<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T03:22:04Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:7660513" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:7660513</identifier>
        <datestamp>2020-11-18</datestamp>
        <setSpec>plosone</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">PLoS One</journal-id>
              <journal-id journal-id-type="iso-abbrev">PLoS One</journal-id>
              <journal-id journal-id-type="publisher-id">plos</journal-id>
              <journal-id journal-id-type="pmc">plosone</journal-id>
              <journal-title-group>
                <journal-title>PLoS ONE</journal-title>
              </journal-title-group>
              <issn pub-type="epub">1932-6203</issn>
              <publisher>
                <publisher-name>Public Library of Science</publisher-name>
                <publisher-loc>San Francisco, CA USA</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC7660513</article-id>
              <article-id pub-id-type="pmcid">PMC7660513</article-id>
              <article-id pub-id-type="pmc-uid">7660513</article-id>
              <article-id pub-id-type="pmid">33180816</article-id>
              <article-id pub-id-type="doi">10.1371/journal.pone.0242169</article-id>
              <article-id pub-id-type="publisher-id">PONE-D-20-21906</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Research Article</subject>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Pain Management</subject>
                    <subj-group>
                      <subject>Hyperalgesia</subject>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Clinical Medicine</subject>
                    <subj-group>
                      <subject>Signs and Symptoms</subject>
                      <subj-group>
                        <subject>Pain</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Neuroscience</subject>
                    <subj-group>
                      <subject>Cognitive Science</subject>
                      <subj-group>
                        <subject>Cognitive Psychology</subject>
                        <subj-group>
                          <subject>Perception</subject>
                          <subj-group>
                            <subject>Sensory Perception</subject>
                          </subj-group>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Psychology</subject>
                    <subj-group>
                      <subject>Cognitive Psychology</subject>
                      <subj-group>
                        <subject>Perception</subject>
                        <subj-group>
                          <subject>Sensory Perception</subject>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Social Sciences</subject>
                  <subj-group>
                    <subject>Psychology</subject>
                    <subj-group>
                      <subject>Cognitive Psychology</subject>
                      <subj-group>
                        <subject>Perception</subject>
                        <subj-group>
                          <subject>Sensory Perception</subject>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Neuroscience</subject>
                    <subj-group>
                      <subject>Sensory Perception</subject>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Physiology</subject>
                    <subj-group>
                      <subject>Sensory Physiology</subject>
                      <subj-group>
                        <subject>Somatosensory System</subject>
                        <subj-group>
                          <subject>Pain Sensation</subject>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Neuroscience</subject>
                    <subj-group>
                      <subject>Sensory Systems</subject>
                      <subj-group>
                        <subject>Somatosensory System</subject>
                        <subj-group>
                          <subject>Pain Sensation</subject>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Neuroscience</subject>
                    <subj-group>
                      <subject>Cognitive Science</subject>
                      <subj-group>
                        <subject>Cognitive Neuroscience</subject>
                        <subj-group>
                          <subject>Reaction Time</subject>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Neuroscience</subject>
                    <subj-group>
                      <subject>Cognitive Neuroscience</subject>
                      <subj-group>
                        <subject>Reaction Time</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Pharmacology</subject>
                    <subj-group>
                      <subject>Drugs</subject>
                      <subj-group>
                        <subject>Analgesics</subject>
                        <subj-group>
                          <subject>Opioids</subject>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Pain Management</subject>
                    <subj-group>
                      <subject>Analgesics</subject>
                      <subj-group>
                        <subject>Opioids</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Pharmacology</subject>
                    <subj-group>
                      <subject>Drugs</subject>
                      <subj-group>
                        <subject>Opioids</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Research and Analysis Methods</subject>
                  <subj-group>
                    <subject>Research Design</subject>
                    <subj-group>
                      <subject>Clinical Research Design</subject>
                      <subj-group>
                        <subject>Adverse Events</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Biochemistry</subject>
                    <subj-group>
                      <subject>Neurochemistry</subject>
                      <subj-group>
                        <subject>Neurochemicals</subject>
                        <subj-group>
                          <subject>Opiates</subject>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Neuroscience</subject>
                    <subj-group>
                      <subject>Neurochemistry</subject>
                      <subj-group>
                        <subject>Neurochemicals</subject>
                        <subj-group>
                          <subject>Opiates</subject>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>High-dose naloxone: Effects by late administration on pain and hyperalgesia following a human heat injury model. A randomized, double-blind, placebo-controlled, crossover trial with an enriched enrollment design</article-title>
                <alt-title alt-title-type="running-head">Unmasking latent sensitization by high-dose naloxone in humans</alt-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-2203-7050</contrib-id>
                  <name>
                    <surname>Springborg</surname>
                    <given-names>Anders Deichmann</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Formal analysis</role>
                  <role content-type="https://casrai.org/credit/">Investigation</role>
                  <role content-type="https://casrai.org/credit/">Project administration</role>
                  <role content-type="https://casrai.org/credit/">Resources</role>
                  <role content-type="https://casrai.org/credit/">Validation</role>
                  <role content-type="https://casrai.org/credit/">Visualization</role>
                  <role content-type="https://casrai.org/credit/">Writing – original draft</role>
                  <role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role>
                  <xref ref-type="aff" rid="aff001">
                    <sup>1</sup>
                  </xref>
                  <xref ref-type="corresp" rid="cor001">*</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Jensen</surname>
                    <given-names>Elisabeth Kjær</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Investigation</role>
                  <role content-type="https://casrai.org/credit/">Project administration</role>
                  <role content-type="https://casrai.org/credit/">Resources</role>
                  <role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role>
                  <xref ref-type="aff" rid="aff001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Kreilgaard</surname>
                    <given-names>Mads</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Methodology</role>
                  <role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role>
                  <xref ref-type="aff" rid="aff002">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Petersen</surname>
                    <given-names>Morten Aagaard</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Formal analysis</role>
                  <role content-type="https://casrai.org/credit/">Supervision</role>
                  <role content-type="https://casrai.org/credit/">Validation</role>
                  <role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role>
                  <xref ref-type="aff" rid="aff003">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Papathanasiou</surname>
                    <given-names>Theodoros</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Formal analysis</role>
                  <role content-type="https://casrai.org/credit/">Validation</role>
                  <role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role>
                  <xref ref-type="aff" rid="aff002">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-8598-2880</contrib-id>
                  <name>
                    <surname>Lund</surname>
                    <given-names>Trine Meldgaard</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Supervision</role>
                  <role content-type="https://casrai.org/credit/">Validation</role>
                  <role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role>
                  <xref ref-type="aff" rid="aff002">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Taylor</surname>
                    <given-names>Bradley Kenneth</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Conceptualization</role>
                  <role content-type="https://casrai.org/credit/">Funding acquisition</role>
                  <role content-type="https://casrai.org/credit/">Methodology</role>
                  <role content-type="https://casrai.org/credit/">Supervision</role>
                  <role content-type="https://casrai.org/credit/">Validation</role>
                  <role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role>
                  <xref ref-type="aff" rid="aff004">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Werner</surname>
                    <given-names>Mads Utke</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Conceptualization</role>
                  <role content-type="https://casrai.org/credit/">Formal analysis</role>
                  <role content-type="https://casrai.org/credit/">Funding acquisition</role>
                  <role content-type="https://casrai.org/credit/">Methodology</role>
                  <role content-type="https://casrai.org/credit/">Resources</role>
                  <role content-type="https://casrai.org/credit/">Supervision</role>
                  <role content-type="https://casrai.org/credit/">Validation</role>
                  <role content-type="https://casrai.org/credit/">Visualization</role>
                  <role content-type="https://casrai.org/credit/">Writing – original draft</role>
                  <role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role>
                  <xref ref-type="aff" rid="aff001">
                    <sup>1</sup>
                  </xref>
                  <xref ref-type="aff" rid="aff005">
                    <sup>5</sup>
                  </xref>
                </contrib>
              </contrib-group>
              <aff id="aff001">
                <label>1</label>
                <addr-line>Neuroscience Center, Copenhagen University Hospitals, Copenhagen, Denmark</addr-line>
              </aff>
              <aff id="aff002">
                <label>2</label>
                <addr-line>Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark</addr-line>
              </aff>
              <aff id="aff003">
                <label>3</label>
                <addr-line>The Research Unit, Department of Palliative Medicine, Copenhagen University Hospitals, Copenhagen, Denmark</addr-line>
              </aff>
              <aff id="aff004">
                <label>4</label>
                <addr-line>Department of Anesthesiology, Pittsburgh Center for Pain Research, and the Pittsburgh Project to End Opioid Misuse, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America</addr-line>
              </aff>
              <aff id="aff005">
                <label>5</label>
                <addr-line>Department of Clinical Sciences, Lund University, Lund, Sweden</addr-line>
              </aff>
              <contrib-group>
                <contrib contrib-type="editor">
                  <name>
                    <surname>Farag</surname>
                    <given-names>Ehab</given-names>
                  </name>
                  <role>Editor</role>
                  <xref ref-type="aff" rid="edit1"/>
                </contrib>
              </contrib-group>
              <aff id="edit1">
                <addr-line>Cleveland Clinic, UNITED STATES</addr-line>
              </aff>
              <author-notes>
                <fn fn-type="COI-statement" id="coi001">
                  <p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p>
                </fn>
                <corresp id="cor001">* E-mail: <email>andersspringborg@gmail.com</email></corresp>
              </author-notes>
              <pub-date pub-type="epub">
                <day>12</day>
                <month>11</month>
                <year>2020</year>
              </pub-date>
              <pub-date pub-type="collection">
                <year>2020</year>
              </pub-date>
              <volume>15</volume>
              <issue>11</issue>
              <elocation-id>e0242169</elocation-id>
              <history>
                <date date-type="received">
                  <day>3</day>
                  <month>8</month>
                  <year>2020</year>
                </date>
                <date date-type="accepted">
                  <day>27</day>
                  <month>10</month>
                  <year>2020</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© 2020 Springborg et al</copyright-statement>
                <copyright-year>2020</copyright-year>
                <copyright-holder>Springborg et al</copyright-holder>
                <license xlink:href="http://creativecommons.org/licenses/by/4.0/">
                  <license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf" xlink:href="pone.0242169.pdf"/>
              <abstract>
                <p>Severe chronic postsurgical pain has a prevalence of 4–10% in the surgical population. The underlying nociceptive mechanisms have not been well characterized. Following the late resolution phase of an inflammatory injury, high-dose μ-opioid-receptor inverse agonists reinstate hypersensitivity to nociceptive stimuli. This unmasking of latent pain sensitization has been a consistent finding in rodents while only observed in a limited number of human volunteers. Latent sensitization could be a potential triggering venue in chronic postsurgical pain. The objective of the present trial was in detail to examine the association between injury-induced secondary hyperalgesia and naloxone-induced unmasking of latent sensitization. Healthy volunteers (n = 80) received a cutaneous heat injury (47°C, 420 s, 12.5 cm<sup>2</sup>). Baseline secondary hyperalgesia areas were assessed 1 h post-injury. Utilizing an enriched enrollment design, subjects with a magnitude of secondary hyperalgesia areas in the upper quartile (‘high-sensitizers’ [n = 20]) and the lower quartile (‘low-sensitizers’ [n = 20]) were selected for further study. In four consecutive experimental sessions (Sessions 1 to 4), the subjects at two sessions (Sessions 1 and 3) received a cutaneous heat injury followed 168 h later (Sessions 2 and 4) by a three-step target-controlled intravenous infusion of naloxone (3.25 mg/kg), or normal saline. Assessments of secondary hyperalgesia areas were made immediately before and stepwise during the infusions. Simple univariate statistics revealed no significant differences in secondary hyperalgesia areas between naloxone and placebo treatments (P = 0.215), or between ‘high-sensitizers’ and ‘low-sensitizers’ (P = 0.757). In a mixed-effects model, secondary hyperalgesia areas were significantly larger following naloxone as compared to placebo for ‘high-sensitizers’ (P &lt; 0.001), but not ‘low-sensitizers’ (P = 0.651). Although we could not unequivocally demonstrate naloxone-induced reinstatement of heat injury-induced hyperalgesia, further studies in clinical postsurgical pain models are warranted.</p>
              </abstract>
              <funding-group>
                <funding-statement>The trial received financial support by Aase og Ejnar Danielsens Fond (<ext-link ext-link-type="uri" xlink:href="https://danielsensfond.dk/">https://danielsensfond.dk/</ext-link>) grant number 10-001534 to MUW, Brødrene Hartmanns Fond (<ext-link ext-link-type="uri" xlink:href="https://www.hartmannfonden.dk/">https://www.hartmannfonden.dk/</ext-link>) grant number A28468 to MUW, Augustinus Fonden (<ext-link ext-link-type="uri" xlink:href="https://augustinusfonden.dk/">https://augustinusfonden.dk/</ext-link>) grant number 15-1724 to MUW, and the United States National Institutes of Health (National Institute on Drug Abuse [NIDA]; <ext-link ext-link-type="uri" xlink:href="https://www.drugabuse.gov/">https://www.drugabuse.gov/</ext-link>) grant number R01DA037621 to BKT and MUW. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement>
              </funding-group>
              <counts>
                <fig-count count="6"/>
                <table-count count="6"/>
                <page-count count="22"/>
              </counts>
              <custom-meta-group>
                <custom-meta id="data-availability">
                  <meta-name>Data Availability</meta-name>
                  <meta-value>All relevant data are within the manuscript and its <xref ref-type="sec" rid="sec062">Supporting Information</xref> files.</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
            <notes>
              <title>Data Availability</title>
              <p>All relevant data are within the manuscript and its <xref ref-type="sec" rid="sec062">Supporting Information</xref> files.</p>
            </notes>
          </front>
          <body>
            <sec sec-type="intro" id="sec001">
              <title>Introduction</title>
              <p>The endogenous opioid analgesia system can be impaired or altered in chronic pain conditions [<xref rid="pone.0242169.ref001" ref-type="bibr">1</xref>–<xref rid="pone.0242169.ref004" ref-type="bibr">4</xref>], playing a putative pathophysiological role in the transition from acute to chronic pain [<xref rid="pone.0242169.ref005" ref-type="bibr">5</xref>–<xref rid="pone.0242169.ref007" ref-type="bibr">7</xref>]. Naloxone and naltrexone are μ-opioid-receptor (MOR) inverse agonists [<xref rid="pone.0242169.ref006" ref-type="bibr">6</xref>] used in experimental research to determine the activity of the endogenous opioid analgesia system [<xref rid="pone.0242169.ref008" ref-type="bibr">8</xref>, <xref rid="pone.0242169.ref009" ref-type="bibr">9</xref>]. Naloxone produces either hypoalgesic or hyperalgesic responses to nociceptive stimulation, depending on the dose administered [<xref rid="pone.0242169.ref010" ref-type="bibr">10</xref>]. Studies in rodents indicate that endogenous MOR constitutive activity masks a process called latent sensitization [<xref rid="pone.0242169.ref006" ref-type="bibr">6</xref>], defined as an increased responsiveness of nociceptive neurons to afferent input induced by either injury, chronic opioid administration, or physiological stress. Latent sensitization can persist in the absence of behavioral signs of hypersensitivity and outlasts the duration of tissue healing. It can be revealed upon administration of an opioid receptor inverse agonist, leading to reinstatement of hyperalgesia in rodents [<xref rid="pone.0242169.ref005" ref-type="bibr">5</xref>, <xref rid="pone.0242169.ref006" ref-type="bibr">6</xref>, <xref rid="pone.0242169.ref011" ref-type="bibr">11</xref>, <xref rid="pone.0242169.ref012" ref-type="bibr">12</xref>].</p>
              <p>In an initial randomized, controlled, crossover trial design, we reported that an intravenous dose of naloxone (21 microg/kg), delivered 72 h after a cutaneous heat injury (CHI), failed to reinstate hyperalgesia in healthy human subjects [<xref rid="pone.0242169.ref013" ref-type="bibr">13</xref>]. In a follow-up trial using a higher dose of naloxone (2 mg/kg), four out of twelve subjects demonstrated reinstatement of hyperalgesia [<xref rid="pone.0242169.ref014" ref-type="bibr">14</xref>]. Reinstatement of latent sensitization, if consistently present in humans may constitute one of the basic trigger mechanisms in development of chronic pain states, e.g. chronic postsurgical pain.</p>
              <p>Furthermore, we noticed that the subjects developing reinstatement of hyperalgesia were subjects with larger initial areas of secondary hyperalgesia (SHA), leading us to hypothesize that latent sensitization occurs more often in ‘high-sensitizers’ as compared to ‘low-sensitizers’. If the hypothesis is validated, the enriched design could be used in future trials to determine indicators of vulnerability to chronic postsurgical pain [<xref rid="pone.0242169.ref014" ref-type="bibr">14</xref>].</p>
              <p>The objectives of the current trial were, first, to replicate [<xref rid="pone.0242169.ref015" ref-type="bibr">15</xref>] our previous latent sensitization trial applying a larger sample size. Second, using an enriched enrollment design, to examine whether ‘high-sensitizers’ express larger hyperalgesia areas after a naloxone challenge than ‘low-sensitizers’.</p>
            </sec>
            <sec sec-type="materials|methods" id="sec002">
              <title>Materials and methods</title>
              <sec id="sec003">
                <title>Trial management</title>
                <p>The trial was approved by the Committee of Health Research Ethics of the Capital Region (H-15018869), the Danish Medicines Agency (2015–005426–19), and the Data Inspection Authority of the Capital Region (RH-2015-284, I-suite no. 04296). Trial registrations were additionally in EUDRACT (2015-005426-19, registered on January 22, 2016) and ClinicalTrials.gov (NCT02684669, registered on February 10, 2016), with the principal investigator MUW. The trial protocol with detailed methodological information has been published [<xref rid="pone.0242169.ref016" ref-type="bibr">16</xref>] and the original approved protocol and the CONSORT checklist are available as supporting information (<xref ref-type="supplementary-material" rid="pone.0242169.s003">S1 Protocol</xref>; <xref ref-type="supplementary-material" rid="pone.0242169.s001">S1 Checklist</xref>).</p>
              </sec>
              <sec id="sec004">
                <title>Participants</title>
                <p>Participants were recruited from a registry of previously completed experimental pain studies at the Neuroscience Center, Copenhagen University Hospitals and by an advertisement at the Danish website forsoegsperson.dk (Inclusion and exclusion criteria <xref rid="pone.0242169.t001" ref-type="table">Table 1</xref>). Additionally, the advertisement was posted on <ext-link ext-link-type="uri" xlink:href="http://facebook.com">facebook.com</ext-link> and hung up on bulletin boards at the University of Copenhagen. Following written and verbal information signed informed consents were obtained from all subjects prior to any assessments. The enrollment process was performed by the corresponding author (ADS). The CONSORT flow diagram shows the included subjects in each session of the trial (<xref ref-type="fig" rid="pone.0242169.g001">Fig 1</xref>). The complete date range for participant recruitment and follow-up was February 22, 2016 to October 1, 2016.</p>
                <fig id="pone.0242169.g001" orientation="portrait" position="float">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0242169.g001</object-id>
                  <label>Fig 1</label>
                  <caption>
                    <title>CONSORT flow diagram.</title>
                    <p>A total of 170 individuals replied to the advertisement. Ninety-four subjects were assessed for general eligibility on an enrichment selection session (Session <bold>0</bold>). Twelve subjects were excluded before the assessments, three tested positive for tetrahydrocannabinol (THC) in their urine, one used prescription drugs and seven had scars or tattoos in the assessment areas. Eighty-three subjects received a cutaneous heat injury (CHI) on Session <bold>0</bold>. Subsequently, three subjects were excluded, two subjects did not develop secondary hyperalgesia areas (SHAs), and one subject had a vasovagal syncope following the CHI. Eighty subjects’ SHAs were analyzed and ranked according to magnitude, assessed by planimetric measurements. Through an enrichment process, 40 subjects with SHAs in the two middle quartiles (Q2/Q3) were discontinued, while the 20 subjects belonging to the lower quartile (Q1) and the 20 subjects belonging to the upper quartile (Q4) were randomized and continued to the experimental sessions. Two subjects from Q4 were, however, excluded before the allocation procedure in Session <bold>1</bold> for reasons unrelated to the trial, one subject was unavailable, and another was diagnosed with acute lymphocytic leukemia (ALL). All other subjects completed per-protocol the trial sessions, and the final analysis, thus, included 38 subjects.</p>
                  </caption>
                  <graphic xlink:href="pone.0242169.g001"/>
                </fig>
                <table-wrap id="pone.0242169.t001" orientation="portrait" position="float">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0242169.t001</object-id>
                  <label>Table 1</label>
                  <caption>
                    <title>Inclusion and exclusion criteria.</title>
                  </caption>
                  <alternatives>
                    <graphic id="pone.0242169.t001g" xlink:href="pone.0242169.t001"/>
                    <table frame="hsides" rules="groups">
                      <colgroup span="1">
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                      </colgroup>
                      <thead>
                        <tr>
                          <th align="left" rowspan="1" colspan="1">
                            <bold>Inclusion criteria</bold>
                          </th>
                          <th align="left" rowspan="1" colspan="1">
                            <bold>Exclusion criteria</bold>
                          </th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td align="left" style="background-color:#CCCCCC" rowspan="1" colspan="1">Healthy male</td>
                          <td align="left" style="background-color:#CCCCCC" rowspan="1" colspan="1">Participant does not speak or understands Danish</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Age above 18 years and below 35 years</td>
                          <td align="left" rowspan="1" colspan="1">Participant cannot cooperate with the investigation</td>
                        </tr>
                        <tr>
                          <td align="left" style="background-color:#CCCCCC" rowspan="1" colspan="1">Signed informed consent</td>
                          <td align="left" style="background-color:#CCCCCC" rowspan="1" colspan="1">Allergic reaction against morphine or other opioids (incl. naloxone)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Urine sample without traces of opioids</td>
                          <td align="left" rowspan="1" colspan="1">Alcohol or drug abuse</td>
                        </tr>
                        <tr>
                          <td align="left" style="background-color:#CCCCCC" rowspan="1" colspan="1">ASA I</td>
                          <td align="left" style="background-color:#CCCCCC" rowspan="1" colspan="1">Use of psychotropic drugs (exception of SSRI)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Body mass index: 18 &lt; BMI &lt; 30 kg/m<sup>2</sup></td>
                          <td align="left" rowspan="1" colspan="1">Neurologic or psychiatric disease</td>
                        </tr>
                        <tr>
                          <td align="left" style="background-color:#CCCCCC" rowspan="1" colspan="1"/>
                          <td align="left" style="background-color:#CCCCCC" rowspan="1" colspan="1">Signs of neuropathy in the examination region</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"/>
                          <td align="left" rowspan="1" colspan="1">Previous severe trauma to the lower legs with sequelae</td>
                        </tr>
                        <tr>
                          <td align="left" style="background-color:#CCCCCC" rowspan="1" colspan="1"/>
                          <td align="left" style="background-color:#CCCCCC" rowspan="1" colspan="1">Scarring or tattoos in the test region</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"/>
                          <td align="left" rowspan="1" colspan="1">Chronic pain condition</td>
                        </tr>
                        <tr>
                          <td align="left" style="background-color:#CCCCCC" rowspan="1" colspan="1"/>
                          <td align="left" style="background-color:#CCCCCC" rowspan="1" colspan="1">Regular use of analgesic drugs</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"/>
                          <td align="left" rowspan="1" colspan="1">Use of prescription drugs one week before the trial</td>
                        </tr>
                        <tr>
                          <td align="left" style="background-color:#CCCCCC" rowspan="1" colspan="1"/>
                          <td align="left" style="background-color:#CCCCCC" rowspan="1" colspan="1">Use of over-the-counter drugs 48 hours before the trial</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"/>
                          <td align="left" rowspan="1" colspan="1">Does not develop measurable secondary hyperalgesia areas after the mild heat injury</td>
                        </tr>
                      </tbody>
                    </table>
                  </alternatives>
                  <table-wrap-foot>
                    <fn id="t001fn001">
                      <p><bold>ASA</bold>: American Society of Anesthesiology’s physical status classification system; <bold>BMI</bold>: Body mass index; <bold>SSRI</bold>: Selective serotonin reuptake inhibitors.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <p>Females were not allowed to participate in the study, since it cannot be excluded that exposure to the supra-pharmacological dose (high-dose) of naloxone may cause teratogenic effects: pregnancy tests are not reliable indicators of a gestational age of less than five weeks. The pregnancy prevention measures, e.g. mechanical or hormonal, have an anti-conception success rate below 100%.</p>
              </sec>
              <sec id="sec005">
                <title>Laboratory environment</title>
                <p>The experimental procedures took place at the Multidisciplinary Pain Center, Neuroscience Center, Copenhagen University Hospital, and were performed in a quiet, daylighted room (22–25°C; relative humidity 20%–45%). Participants adopted a relaxed, recumbent position during sensory assessments. Sensory assessments were performed between 8:00 AM and 4:00 PM.</p>
              </sec>
              <sec id="sec006">
                <title>Trial design</title>
                <p>A randomized, double-blinded, placebo-controlled, crossover trial with an enriched design.</p>
                <sec id="sec007">
                  <title>Enrichment</title>
                  <p>The trial included an enrichment selection session (Session <bold>0</bold>) and four experimental sessions (Sessions <bold>1</bold> to <bold>4</bold>; <xref ref-type="fig" rid="pone.0242169.g002">Fig 2</xref>). The enrichment enrollment selection [<xref rid="pone.0242169.ref017" ref-type="bibr">17</xref>, <xref rid="pone.0242169.ref018" ref-type="bibr">18</xref>] was based on the magnitude of SHA following a CHI, thus separating ‘high-sensitizers’ (upper quartile [Q4]) and ‘low-sensitizers’ (lower quartile [Q1]), from ‘intermediate-sensitizers’ (Q2/Q3), who were excluded from further trial participation. Subjects in Q4 (n = 20) and Q1 (n = 20) continued to experimental Sessions <bold>1</bold> to <bold>4</bold>. However, two subjects from Q4 were excluded before the allocation procedure in Session <bold>1</bold> for reasons unrelated to the study (<xref ref-type="fig" rid="pone.0242169.g001">Fig 1</xref>).</p>
                  <fig id="pone.0242169.g002" orientation="portrait" position="float">
                    <object-id pub-id-type="doi">10.1371/journal.pone.0242169.g002</object-id>
                    <label>Fig 2</label>
                    <caption>
                      <title>General trial layout.</title>
                      <p>Cutaneous heat injuries were induced on an enrichment session (Session <bold>0</bold>), a selection process uncovering ‘high-sensitizers’ (large secondary hyperalgesia areas: upper quartile [Q4]) and ‘low-sensitizers’ (small secondary hyperalgesia areas: lower quartile [Q1]). Sessions <bold>1</bold> and <bold>3</bold> included repeat cutaneous heat injuries in ‘high- and low-sensitizers’. Target-controlled infusion sessions were Sessions <bold>2</bold> and <bold>4</bold>, with randomized allocation between placebo and naloxone. The time interval between Sessions <bold>1</bold> and <bold>2</bold>, and, Sessions <bold>3</bold> and <bold>4</bold>, was 7 days. The time interval between Sessions <bold>0</bold> and <bold>3</bold> was &gt; 8 weeks.</p>
                    </caption>
                    <graphic xlink:href="pone.0242169.g002"/>
                  </fig>
                </sec>
                <sec id="sec008">
                  <title>Randomization procedure</title>
                  <p>After Session <bold>0</bold> a computer-generated random permutation of numbers 1 to 40 was applied to subjects in Q1 (n = 20) and Q4 (n = 20; <ext-link ext-link-type="uri" xlink:href="http://randomization.com">randomization.com</ext-link>). Each subject from Q1 and Q4 then received a sequential rank order according to the magnitude of the SHA (1 to 20; 61 to 80). These sequential rank numbers were then consecutively paired with the list of random permutation of numbers, rendering randomization of the order of ‘high- and low-sensitizers’. The subjects were then invited to participate in the experimental sessions in this randomized order. This randomization procedure was performed by the principal investigator (MUW; not participating in the assessments), and source data were locked away safely. The examiners were blinded to the subject´s ‘sensitizer’-affiliation.</p>
                  <p>Computer-Generated sequence randomization, using blocks of four subjects (<ext-link ext-link-type="uri" xlink:href="http://randomization.com">randomization.com</ext-link>), was performed by the hospital pharmacy (Skanderborg Pharmacy, Skanderborg, DENMARK), responsible for manufacturing, labeling and packaging of the drugs. Two sets of non-transparent, sealed envelopes, containing information on treatment allocation order for each participant, were prepared and stored securely while an additional envelope was kept in the examination room, to be opened in case of a medical emergency. Both participants and investigators were blinded to the treatment sequence throughout the trial.</p>
                </sec>
              </sec>
              <sec id="sec009">
                <title>Cutaneous heat injury</title>
                <p>The CHIs were induced on the thigh (Session <bold>0</bold>) and the medial aspect of the calf (Session <bold>1</bold>: right calf; Session <bold>3</bold>: left calf) with a computerized contact thermode system (MSA Thermal Stimulator, Somedic AB, Hörby, SWEDEN; heating area: 2.5 x 5.0 cm2; baseline: 32°C; ramp rate: ± 1°C/s; plateau: 47°C; duration: 420 seconds) [<xref rid="pone.0242169.ref013" ref-type="bibr">13</xref>, <xref rid="pone.0242169.ref019" ref-type="bibr">19</xref>, <xref rid="pone.0242169.ref020" ref-type="bibr">20</xref>]. The homotopic testing areas were meticulously delineated at each session.</p>
              </sec>
              <sec id="sec010">
                <title>Drug administration</title>
                <p>In Sessions <bold>2</bold> and <bold>4</bold>, target-controlled infusions (TCI) of naloxone or placebo were administered 168 h after induction of the CHI (<xref ref-type="fig" rid="pone.0242169.g003">Fig 3</xref>). The TCI-algorithm, based on previously reported population pharmacokinetic data [<xref rid="pone.0242169.ref021" ref-type="bibr">21</xref>], was calculated by the software NONMEM (7.3 ICON Development Solutions, Manchester, U.K. [property of UCSF, CA]), using computer simulations based on a population-kinetic model with 2,000 simulated administrations distributed on ten subjects. The estimated mean (10% and 90% percentiles) plasma concentrations of naloxone at each of the three TCI-steps are illustrated in <xref ref-type="fig" rid="pone.0242169.g004">Fig 4</xref> [<xref rid="pone.0242169.ref022" ref-type="bibr">22</xref>] with each TCI-step containing a 1 min bolus and a 24 min continuous infusion. A total dose of naloxone 3.25 mg/kg (4 mg/mL) vis-á-vis normal saline 0.81 mL/kg was administered (<xref rid="pone.0242169.t002" ref-type="table">Table 2</xref>). During the last 10 min of each 25 min step, plasma concentrations were considered to be stable, and therefore sensory assessments were performed (<xref ref-type="fig" rid="pone.0242169.g004">Fig 4</xref>).</p>
                <fig id="pone.0242169.g003" orientation="portrait" position="float">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0242169.g003</object-id>
                  <label>Fig 3</label>
                  <caption>
                    <title>Trial timeline.</title>
                    <p>Session <bold>1</bold> and <bold>3</bold> (cf. <xref ref-type="fig" rid="pone.0242169.g001">Fig 1</xref>) included baseline assessments (green rectangle, 0 min), induction of a cutaneous heat injury (CHI, red rectangle, 20 min) and post-injury assessments (blue rectangles: 1 h 27 min and 2 h 27 min). Session <bold>2</bold> and <bold>4</bold> (cf. <xref ref-type="fig" rid="pone.0242169.g001">Fig 1</xref>) included a pre-drug assessment (magenta rectangle; post-injury 165 h), drug-infusions (naloxone or placebo; 167 h 35 min, 168 h 0 min, and 168 h 25 min), and assessments during target-controlled infusion (TCI; grey rectangles; 167 h 35 min, 168 h 0 min, and 168 h 25 min). The estimated TCI plasma concentrations are superimposed in dashed red line. Numbers (1 to 3) during the infusion period, indicate the three TCI-steps. Assessments included secondary hyperalgesia areas and online reaction time indicated by green stars and pin-prick pain thresholds indicated by red stars.</p>
                  </caption>
                  <graphic xlink:href="pone.0242169.g003"/>
                </fig>
                <fig id="pone.0242169.g004" orientation="portrait" position="float">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0242169.g004</object-id>
                  <label>Fig 4</label>
                  <caption>
                    <title>Target-controlled infusion.</title>
                    <p>Test-algorithm Session <bold>2</bold> and <bold>4</bold> for subjects with superimposed naloxone plasma-concentration curves. Median plasma-concentration (red) with 10% and 90% percentiles ranges (dashed black lines) during a three-step target-controlled infusion (TCI). Naloxone was administered at step 1 (ST1: 15 min to 25 min) with 0.25 mg/kg, step 2 (ST2: 39 min to 49 min) 0.75 mg/kg, and step 3 (ST3: 65 min to 75 min) 2.25 mg/kg. Magenta columns represent ratings with Clinical Opiate Withdrawal Scale (COWS) and blue columns indicate sensory testing (BL and ST1 to ST3: secondary hyperalgesia areas; BL and ST3: pin-prick pain thresholds). <bold>BL</bold>: baseline assessments [<xref rid="pone.0242169.ref022" ref-type="bibr">22</xref>].</p>
                  </caption>
                  <graphic xlink:href="pone.0242169.g004"/>
                </fig>
                <table-wrap id="pone.0242169.t002" orientation="portrait" position="float">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0242169.t002</object-id>
                  <label>Table 2</label>
                  <caption>
                    <title>Target-controlled infusion (TCI) of naloxone.</title>
                  </caption>
                  <alternatives>
                    <graphic id="pone.0242169.t002g" xlink:href="pone.0242169.t002"/>
                    <table frame="hsides" rules="groups">
                      <colgroup span="1">
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                      </colgroup>
                      <thead>
                        <tr>
                          <th align="center" rowspan="1" colspan="1">
                            <bold>Step</bold>
                          </th>
                          <th align="center" rowspan="1" colspan="1">
                            <bold>TCI</bold>
                          </th>
                          <th align="center" rowspan="1" colspan="1">
                            <bold>Time (min)</bold>
                          </th>
                          <th align="center" rowspan="1" colspan="1">
                            <bold>Dose (mg/kg)</bold>
                          </th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td align="center" rowspan="2" colspan="1">
                            <bold>
                              <bold>Step 1</bold>
                            </bold>
                          </td>
                          <td align="center" rowspan="1" colspan="1">Bolus 1</td>
                          <td align="center" rowspan="1" colspan="1">0–1</td>
                          <td align="center" rowspan="1" colspan="1">0.02</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">Infusion 1</td>
                          <td align="center" rowspan="1" colspan="1">1–25</td>
                          <td align="center" rowspan="1" colspan="1">0.23</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="2" colspan="1">
                            <bold>
                              <bold>Step 2</bold>
                            </bold>
                          </td>
                          <td align="center" rowspan="1" colspan="1">Bolus 2</td>
                          <td align="center" rowspan="1" colspan="1">25–26</td>
                          <td align="center" rowspan="1" colspan="1">0.06</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">Infusion 2</td>
                          <td align="center" rowspan="1" colspan="1">26–50</td>
                          <td align="center" rowspan="1" colspan="1">0.69</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="2" colspan="1">
                            <bold>
                              <bold>Step 3</bold>
                            </bold>
                          </td>
                          <td align="center" rowspan="1" colspan="1">Bolus 3</td>
                          <td align="center" rowspan="1" colspan="1">50–51</td>
                          <td align="center" rowspan="1" colspan="1">0.18</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">Infusion 3</td>
                          <td align="center" rowspan="1" colspan="1">51–75</td>
                          <td align="center" rowspan="1" colspan="1">2.07</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1"/>
                          <td align="center" rowspan="1" colspan="1">TOTAL</td>
                          <td align="center" rowspan="1" colspan="1">75</td>
                          <td align="center" rowspan="1" colspan="1">3.25</td>
                        </tr>
                      </tbody>
                    </table>
                  </alternatives>
                  <table-wrap-foot>
                    <fn id="t002fn001">
                      <p>Target-controlled infusion (TCI) of naloxone (4 mg/ml): timeline and dose/kg for the three steps: <bold>Step 1</bold> (Bolus 1 + Infusion 1), <bold>Step 2</bold> (Bolus 2 + Infusion 2), and <bold>Step 3</bold> (Bolus 3 + Infusion 3).</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <sec id="sec011">
                  <title>Monitoring</title>
                  <p>Vital sign monitoring in TCI-sessions (Sessions <bold>2</bold> and <bold>4</bold>) was with continuous three-lead electrocardiogram, heart rate, pulse oximetry, noninvasive arterial blood pressure, and respiratory rate.</p>
                </sec>
              </sec>
              <sec id="sec012">
                <title>Primary outcome</title>
                <sec id="sec013">
                  <title>Secondary hyperalgesia areas</title>
                  <p>Areas of secondary hyperalgesia were assessed by a weighted-pin instrument (128 mN; MRC Systems, Heidelberg, GERMANY) [<xref rid="pone.0242169.ref020" ref-type="bibr">20</xref>] delivering punctate stimuli (stimulus area: 0.049 mm<sup>2</sup>) in Sessions <bold>0</bold>, <bold>1</bold>, and <bold>3</bold>: before, and 1 and 2 h after the CHI (<xref ref-type="fig" rid="pone.0242169.g002">Fig 2</xref>); and Sessions <bold>2</bold> and <bold>4</bold>: 165 to 169 h after the CHI (baseline: 165 h 0 min; during TCI: 167 h 35 min, 168 h 0 min, and 169 h 25 min). The borders of the SHAs were determined by stimulating along eight symmetric lines starting in normal skin and converging towards the center of the CHI. The participant reported when the punctate sensation changed from an innocuous pin-prick to a stinging, smarting, or unpleasant sensation. The corners of the octagon were marked on the skin and transferred to a clear acetate sheet. The SHA was determined by planimetrics using a vector-based drawing program (Canvas 12.0, ACD Systems International, BC, CANADA).</p>
                </sec>
              </sec>
              <sec id="sec014">
                <title>Other outcomes</title>
                <sec id="sec015">
                  <title>Mechanical pain thresholds</title>
                  <p>Pin-prick pain thresholds (PPTs) were assessed in the primary and secondary injury area by punctate stimulators (8, 16, 32, 64, 128, 256, and 512 mN) using a modified Dixon procedure (<xref ref-type="fig" rid="pone.0242169.g003">Fig 3</xref>) [<xref rid="pone.0242169.ref023" ref-type="bibr">23</xref>, <xref rid="pone.0242169.ref024" ref-type="bibr">24</xref>]. Pin-prick pain thresholds were assessed in Sessions <bold>0</bold>, <bold>1</bold>, and <bold>3</bold> (baseline, 1, and 2 h post-injury) and Sessions <bold>2</bold> and <bold>4</bold> (before the infusion 165 h 0 min and during Step 3 of the TCI 168 h 25 min). The punctate stimulators were applied perpendicularly to the skin, each five times. The lowest nominal value of the punctate stimulator eliciting ≥ 3 stinging, smarting, or unpleasant sensations indicated the PPT. The median value of the four PPTs was used for further analysis. The PPT data was converted to corresponding ordinal values (1 to 8).</p>
                </sec>
                <sec id="sec016">
                  <title>Pain during the cutaneous heat injury</title>
                  <p>During the CHI, pain assessments (Numerical Rating Scale [NRS]; 0 to 10) were made at 0, 30, 60, 120, 180, 240, 300, 360, and 420 s. The CHI-induced pain intensity was calculated using area under the curve per second (AUC/s).</p>
                </sec>
                <sec id="sec017">
                  <title>Clinical opiate withdrawal scale</title>
                  <p>Clinical signs of endogenous opiate withdrawal during the naloxone infusion were assessed by the examiner using the Clinical Opiate Withdrawal Scale (COWS) [<xref rid="pone.0242169.ref025" ref-type="bibr">25</xref>] on Session <bold>0</bold>, and during the TCI-infusion on Sessions <bold>2</bold> and <bold>4</bold> (<xref ref-type="fig" rid="pone.0242169.g004">Fig 4</xref>).</p>
                </sec>
                <sec id="sec018">
                  <title>Psychometric evaluations</title>
                  <p>Since anxiety and depression are well-known psychological parameters intimately associated with pain, participants completed the Hospital Anxiety and Depression Scale (HADS-A/D) [<xref rid="pone.0242169.ref026" ref-type="bibr">26</xref>, <xref rid="pone.0242169.ref027" ref-type="bibr">27</xref>], and the Pain Catastrophizing Scale (PCS) [<xref rid="pone.0242169.ref028" ref-type="bibr">28</xref>, <xref rid="pone.0242169.ref029" ref-type="bibr">29</xref>] at Session <bold>0</bold> before the sensory assessments.</p>
                </sec>
                <sec id="sec019">
                  <title>Online reaction time test</title>
                  <p>Reaction time was tested since it is a measure of vigilance, important during sensory testing. Further, the possible sedating effects of high-dose naloxone was evaluated. Online reaction time was assessed using a computer application showing a red-green traffic light (<ext-link ext-link-type="uri" xlink:href="https://faculty.washington.edu/chudler/java/redgreen.html">https://faculty.washington.edu/chudler/java/redgreen.html</ext-link>; <xref ref-type="fig" rid="pone.0242169.g003">Fig 3</xref>) [<xref rid="pone.0242169.ref030" ref-type="bibr">30</xref>]. Participants were asked to press a button immediately when the light switched from red to green. The median of three measurements indicated the reaction time.</p>
                </sec>
              </sec>
              <sec id="sec020">
                <title>Statistics</title>
                <sec id="sec021">
                  <title>Sample size calculation</title>
                  <p>Data from a previous high-dose naloxone trial (n = 12) [<xref rid="pone.0242169.ref014" ref-type="bibr">14</xref>] in ‘high-sensitizers’ (n = 3), 168 h post-injury, indicated mean (SD) values of SHAs during naloxone infusion of 111.0 cm2 (26.3 cm2) and during placebo infusion 2.1 cm2 (2.5 cm2). Correspondingly for ‘low-sensitizers’ (n = 3), SHAs were 0.9 cm2 (0.6 cm2) and 0.3 cm2 (0.1 cm2), respectively. With a significance level of 0.01 (α) and a power of 0.90 (β = 0.10), the estimated number of individuals needed to reject the null hypothesis in ‘high-sensitizers’ were 5 (effect size 4.3) and in ‘low-sensitizers’ 18 (effect size 1.1; G*Power3.9.1.2, Kiel University, GERMANY). However, because the sample size estimate was based on data with excessive variability, it was decided to include 20 ‘high-sensitizers’ and 20 ‘low-sensitizers’.</p>
                </sec>
                <sec id="sec022">
                  <title>Statistical analysis</title>
                  <p>Data distributions were inferred from residual plots and the Kolmogorov–Smirnov test (SPSS IBM Software 22.0, Chicago, IL; MedCalc Software: version 16.4.3, Mariakerke, BELGIUM). The basic SHA-arithmetic was (NX = naloxone; PLA = placebo):
<disp-formula id="pone.0242169.e001"><alternatives><graphic xlink:href="pone.0242169.e001.jpg" id="pone.0242169.e001g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M1"><mml:mi>Δ</mml:mi><mml:mi>S</mml:mi><mml:mi>H</mml:mi><mml:msub><mml:mrow><mml:mi>A</mml:mi></mml:mrow><mml:mrow><mml:mi>Q</mml:mi><mml:mn>4</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mi>S</mml:mi><mml:mi>H</mml:mi><mml:msub><mml:mrow><mml:mi>A</mml:mi></mml:mrow><mml:mrow><mml:mi>N</mml:mi><mml:mi>X</mml:mi><mml:mspace width="0.25em"/><mml:mi>Q</mml:mi><mml:mn>4</mml:mn></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:mi>S</mml:mi><mml:mi>H</mml:mi><mml:msub><mml:mrow><mml:mi>A</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi><mml:mi>L</mml:mi><mml:mi>A</mml:mi><mml:mspace width="0.25em"/><mml:mi>Q</mml:mi><mml:mn>4</mml:mn></mml:mrow></mml:msub></mml:math></alternatives></disp-formula>
<disp-formula id="pone.0242169.e002"><alternatives><graphic xlink:href="pone.0242169.e002.jpg" id="pone.0242169.e002g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M2"><mml:mi>Δ</mml:mi><mml:mi>S</mml:mi><mml:mi>H</mml:mi><mml:msub><mml:mrow><mml:mi>A</mml:mi></mml:mrow><mml:mrow><mml:mi>Q</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mi>S</mml:mi><mml:mi>H</mml:mi><mml:msub><mml:mrow><mml:mi>A</mml:mi></mml:mrow><mml:mrow><mml:mi>N</mml:mi><mml:mi>X</mml:mi><mml:mspace width="0.25em"/><mml:mi>Q</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:mi>S</mml:mi><mml:mi>H</mml:mi><mml:msub><mml:mrow><mml:mi>A</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi><mml:mi>L</mml:mi><mml:mi>A</mml:mi><mml:mspace width="0.25em"/><mml:mi>Q</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math></alternatives></disp-formula>
<disp-formula id="pone.0242169.e003"><alternatives><graphic xlink:href="pone.0242169.e003.jpg" id="pone.0242169.e003g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M3"><mml:mi>Δ</mml:mi><mml:mi>S</mml:mi><mml:mi>H</mml:mi><mml:mi mathvariant="normal">A</mml:mi><mml:mo>=</mml:mo><mml:mi>Δ</mml:mi><mml:mi>S</mml:mi><mml:mi>H</mml:mi><mml:msub><mml:mrow><mml:mi>A</mml:mi></mml:mrow><mml:mrow><mml:mi>Q</mml:mi><mml:mn>4</mml:mn></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:mi>Δ</mml:mi><mml:mi>S</mml:mi><mml:mi>H</mml:mi><mml:msub><mml:mrow><mml:mi>A</mml:mi></mml:mrow><mml:mrow><mml:mi>Q</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math></alternatives></disp-formula></p>
                  <p>The main analysis used maximal SHA values (SHA<sub>MAX</sub>) during the TCI (independent of TCI-step).</p>
                  <p>The primary outcome SHA was analyzed according to the protocol (<xref ref-type="supplementary-material" rid="pone.0242169.s003">S1 Protocol</xref>) [<xref rid="pone.0242169.ref016" ref-type="bibr">16</xref>], by simple univariate statistics (Wilcoxon signed-rank test, Mann-Whitney, paired or unpaired t test) and by an advanced mixed-effects model. The mixed-effects model was with a random effect for subject, and fixed effects for the variables ‘sensitizers’ (‘high-sensitizers’/’low-sensitizers’), intervention (naloxone/placebo), TCI-step (step 1, 2, 3), time (Session <bold>2</bold>, <bold>4</bold> [added post hoc, see Results—Protocol violations for explanation]), HADS-scores, and PCS-scores for the primary outcome measure SHA. The starting model included all interactions. Main effects and interaction effects were examined. Non-significant factors (P &gt; 0.05), beginning with interactions, were excluded until all included factors attained significance. Carry-over effects were assessed using SHA data from the CHI-sessions (Sessions <bold>1</bold> and <bold>3</bold>).</p>
                  <p>Other outcomes were analyzed by univariate statistics (PPTs, pain during the CHI), ICCs (pain during the CHI), and two-way repeated-measures ANOVA (online reaction time). A P-value &lt; 0.01 was considered statistically significant. Data are given as mean (95% CI) or median (95% CI), as appropriate.</p>
                </sec>
                <sec id="sec023">
                  <title>Validity of the enrichment design</title>
                  <p>To test the validity of the enrichment design (the agreement across Sessions <bold>0</bold>, <bold>1</bold>, and <bold>3)</bold>, ICCs (two-way random model with absolute agreement), and one-way repeated-measures ANOVA or the Friedman test pertaining SHA-data (Session <bold>0</bold>, <bold>1</bold>, and <bold>3</bold>) were calculated. For interpretation purposes, ICCs were categorized as slight/poor (&lt; 0.2), fair (0.2 to 0.4), moderate (0.4 to 0.6), substantial (0.6 to 0.8), and almost perfect (&gt; 0.8) [<xref rid="pone.0242169.ref031" ref-type="bibr">31</xref>].</p>
                </sec>
              </sec>
            </sec>
            <sec sec-type="results" id="sec024">
              <title>Results</title>
              <sec id="sec025">
                <title>Volunteers and trial chronology</title>
                <p>A total of 94 subjects were assessed for eligibility (CONSORT flow diagram <xref ref-type="fig" rid="pone.0242169.g001">Fig 1</xref>), and 83 subjects were enrolled in Session <bold>0</bold> assessments. Three of these subjects were excluded, and the data from the remaining 80 subjects were analyzed per-protocol [<xref rid="pone.0242169.ref016" ref-type="bibr">16</xref>] (data available as supporting information: <xref ref-type="supplementary-material" rid="pone.0242169.s001">S1 Table</xref>). Forty subjects, ‘high-sensitizers’ (Q4; n = 20) and ‘low-sensitizers’ (Q1; n = 20), continued on to Sessions <bold>1</bold> to <bold>4</bold>. Two Q4-subjects were excluded for reasons not related to the trial (<xref ref-type="fig" rid="pone.0242169.g001">Fig 1</xref>; specified in <xref ref-type="supplementary-material" rid="pone.0242169.s004">S1 Adverse</xref> events). Per-protocol data from the remaining 38 subjects were analyzed. Demographic and anthropometric data are presented in <xref rid="pone.0242169.t003" ref-type="table">Table 3</xref>. The first and last trial visits were February 29, 2016 and September 30, 2016, respectively. The time intervals, median (95% CI), between Sessions <bold>0</bold> and <bold>1</bold>, and, Sessions <bold>1</bold> and <bold>3</bold>, were 60 (45–76) days and 47 (41–54) days, respectively.</p>
                <table-wrap id="pone.0242169.t003" orientation="portrait" position="float">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0242169.t003</object-id>
                  <label>Table 3</label>
                  <caption>
                    <title>Demographics and anthropometrics.</title>
                  </caption>
                  <alternatives>
                    <graphic id="pone.0242169.t003g" xlink:href="pone.0242169.t003"/>
                    <table frame="hsides" rules="groups">
                      <colgroup span="1">
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                      </colgroup>
                      <thead>
                        <tr>
                          <th align="left" rowspan="1" colspan="1"/>
                          <th align="center" rowspan="1" colspan="1">
                            <bold>Included (Q4/Q1) (n = 40)</bold>
                          </th>
                          <th align="center" rowspan="1" colspan="1">
                            <bold>Final analyzed (Q4/Q1) (n = 38)</bold>
                          </th>
                          <th align="center" rowspan="1" colspan="1">
                            <bold>Excluded (Q2/Q3) (n = 40)</bold>
                          </th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">
                            <bold>
                              <bold>Age (yrs)</bold>
                            </bold>
                          </td>
                          <td align="center" rowspan="1" colspan="1">23.6 (22.6–24.7)</td>
                          <td align="center" rowspan="1" colspan="1">23.6 (22.6–24.6)</td>
                          <td align="center" rowspan="1" colspan="1">23 (22.0–24.0)<sup>§</sup></td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">
                            <bold>
                              <bold>Height (cm)</bold>
                            </bold>
                          </td>
                          <td align="center" rowspan="1" colspan="1">182.6 (180.3–184.8)</td>
                          <td align="center" rowspan="1" colspan="1">182.8 (180.6–185.1)</td>
                          <td align="center" rowspan="1" colspan="1">182.5 (180.3–184.6)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">
                            <bold>
                              <bold>Weight (kg)</bold>
                            </bold>
                          </td>
                          <td align="center" rowspan="1" colspan="1">79.1 (75.4–82.9)</td>
                          <td align="center" rowspan="1" colspan="1">80.2 (76.6–83.8)</td>
                          <td align="center" rowspan="1" colspan="1">79.3 (75.7–82.9)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">
                            <bold>
                              <bold>BMI (kg/m</bold>
                              <sup>
                                <bold>2</bold>
                              </sup>
                              <bold>)</bold>
                            </bold>
                          </td>
                          <td align="center" rowspan="1" colspan="1">23.7 (22.8–24.6)</td>
                          <td align="center" rowspan="1" colspan="1">24.0 (23.1–24.9)</td>
                          <td align="center" rowspan="1" colspan="1">23.8 (22.9–24.6)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">
                            <bold>
                              <bold>BSA (m</bold>
                              <sup>
                                <bold>2</bold>
                              </sup>
                              <bold>)</bold>
                            </bold>
                          </td>
                          <td align="center" rowspan="1" colspan="1">2.00 (1.94–2.05)</td>
                          <td align="center" rowspan="1" colspan="1">2.01 (1.96–2.07)</td>
                          <td align="center" rowspan="1" colspan="1">2.00 (1.95–2.05)</td>
                        </tr>
                      </tbody>
                    </table>
                  </alternatives>
                  <table-wrap-foot>
                    <fn id="t003fn001">
                      <p>Demographics and anthropometrics for the included group (First quartile [Q1] and fourth quartile [Q4] [see text for explanation]), the final analysis group (Q1/Q4) and the excluded group (Q2/Q3). Values are presented as mean (95% CI) unless otherwise indicated. <sup>§</sup> median (95% CI). <bold>BMI</bold>: body mass index; <bold>BSA</bold>: body surface area.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec id="sec026" sec-type="materials|methods">
                <title>Methodology</title>
                <sec id="sec027">
                  <title>Changes induced by the cutaneous heat injury</title>
                  <p>The CHI induced significant SHAs in both Sessions <bold>1</bold> and <bold>3</bold> (Friedman tests: P &lt; 0.001) and all subjects had measurable SHAs in both sessions. Furthermore, the CHI significantly reduced PPTs in both the primary and secondary areas of hyperalgesia in Sessions <bold>1</bold> and <bold>3</bold> (Friedman tests: P &lt; 0.001).</p>
                </sec>
                <sec id="sec028">
                  <title>Validity of the enrichment procedure</title>
                  <p>The ICCs (95% CI) for the SHA data from the CHI-sessions (Sessions <bold>0</bold>, <bold>1</bold>, and <bold>3</bold>) for Q1 (n = 20), Q4 (n = 18), and Q1 and Q4 combined (n = 38) were 0.59 (0.13–0.82; P = 0.010), 0.58 (0.09–0.83; P = 0.015), and 0.72 (0.52–0.85; P &lt; 0.001), respectively, indicating moderate to substantial agreement across sessions (<xref ref-type="fig" rid="pone.0242169.g005">Fig 5</xref>). A Friedman test showed differences in SHAs between Sessions <bold>0</bold>, <bold>1</bold>, and <bold>3</bold> for Q1 (Chi-square [df]: 13.3 [<xref rid="pone.0242169.ref002" ref-type="bibr">2</xref>], P = 0.001) but not for Q4 (8.1 [<xref rid="pone.0242169.ref002" ref-type="bibr">2</xref>], P = 0.017). Further analysis revealed that SHAs at Session <bold>1</bold> (median [95% CI]: 27.2 [23.9–33.6] cm<sup>2</sup>) was significantly larger than at Session <bold>0</bold> for Q1 (median [95% CI]: 21.2 [19.2–23.9] cm<sup>2</sup>; Wilcoxon signed-rank test: -3.44, P = 0.001).</p>
                  <fig id="pone.0242169.g005" orientation="portrait" position="float">
                    <object-id pub-id-type="doi">10.1371/journal.pone.0242169.g005</object-id>
                    <label>Fig 5</label>
                    <caption>
                      <title>Sensitizer categorization following cutaneous heat injuries.</title>
                      <p>Secondary hyperalgesia areas as measured at baseline on Sessions <bold>0</bold>, <bold>1</bold>, and <bold>3</bold>. Red lines illustrate ‘high-sensitizers’ and blue lines illustrate ‘low-sensitizers’. The blue rectangle shows the Q1 interval and the red rectangle shows the Q4 interval as defined on Session <bold>0</bold>.</p>
                    </caption>
                    <graphic xlink:href="pone.0242169.g005"/>
                  </fig>
                </sec>
                <sec id="sec029">
                  <title>Carry-over effects</title>
                  <p>A trend towards larger SHAs in Session <bold>1</bold> (median [95% CI]: 34.2 [27.2–44.6] cm<sup>2</sup>) compared to Session <bold>3</bold> (median [95% CI]: 28.7 [24.0–42.4] cm<sup>2</sup>; Wilcoxon signed-rank test: P = 0.016), was observed.</p>
                </sec>
              </sec>
              <sec id="sec030">
                <title>Primary outcome</title>
                <sec id="sec031">
                  <title>Pairwise comparison</title>
                  <p>When analyzing SHA<sub>MAX</sub> without partitioning into ‘high-sensitizers’ and ‘low-sensitizers’ there was no significant difference between naloxone (median [95% CI]: 0 [0–0.3] cm<sup>2</sup>) and placebo (median [95% CI]: 0 [0–0] cm<sup>2</sup>; Wilcoxon signed-rank test: P = 0.215; <xref ref-type="fig" rid="pone.0242169.g006">Fig 6</xref>). In the ‘high-sensitizer’ group, no significant difference was demonstrated between naloxone (median [95% CI]: 0 [0–75.5] cm<sup>2</sup>) and placebo (median [95% CI]: 0 [0–11.7] cm<sup>2</sup>; Wilcoxon signed-rank test: P = 0.374). Similarly, in ‘low-sensitizers’, no significant difference was demonstrated between naloxone (median [95% CI]: 0 [0–0] cm<sup>2</sup>) and placebo (median [95% CI]: 0 [0–0] cm<sup>2</sup>; Wilcoxon signed-rank test: P = 0.398). No statistical difference for ΔSHA<sub>MAX</sub> was found between ‘high-sensitizers’ (median [95% CI]: 0 [0–14.4] cm<sup>2</sup>) and ‘low-sensitizers’ (median [95% CI]: 0 [0–0] cm<sup>2</sup>; Mann-Whitney U test: P = 0.757).</p>
                  <fig id="pone.0242169.g006" orientation="portrait" position="float">
                    <object-id pub-id-type="doi">10.1371/journal.pone.0242169.g006</object-id>
                    <label>Fig 6</label>
                    <caption>
                      <title>Magnitude of secondary hyperalgesia areas following naloxone or placebo.</title>
                      <p>Comparison of individual maximum secondary hyperalgesia area (SHA<sub>MAX</sub>) with subtraction of baseline areas after administration of naloxone or placebo. When all subjects were analyzed without partitioning into ‘high- and low-sensitizers’, there were no significant difference between SHAs following naloxone infusion (median [95% CI]: 0 [0–0.3] cm<sup>2</sup>), compared to the placebo infusion (median [95% CI]: 0 [0–0] cm<sup>2</sup>; Wilcoxon signed-rank test: P = 0.215). Furthermore, no significant difference for SHA<sub>MAX</sub> was found between ‘high-sensitizers’ (median [95% CI]: 0 [0–14.4] cm<sup>2</sup>) and ‘low-sensitizers’ (median [95% CI]: 0 [0–0] cm<sup>2</sup>; Mann-Whitney U test: P = 0.757). Red lines represent ‘high-sensitizers’ and blue lines represent ‘low-sensitizers’.</p>
                    </caption>
                    <graphic xlink:href="pone.0242169.g006"/>
                  </fig>
                </sec>
                <sec id="sec032">
                  <title>Mixed-effects model</title>
                  <p>No interactions attained significance. Main effects of intervention (P = 0.015), ‘sensitizers’, TCI-step, HADS-scores, and PCS-scores were not significantly different (<xref rid="pone.0242169.t004" ref-type="table">Table 4</xref>). In the post hoc analysis model (cf. Materials and methods—Statistical analysis; <xref rid="pone.0242169.t005" ref-type="table">Table 5</xref>), where the variable time was included, a significant interaction between intervention*’sensitizers’ (P = 0.002), as well as between ‘sensitizers’*time (P &lt; 0.001) was observed. Regarding the estimates of fixed effects, SHA following naloxone compared to placebo was 35.4 cm<sup>2</sup> (P &lt; 0.001; <xref rid="pone.0242169.t006" ref-type="table">Table 6</xref>) for ‘high-sensitizers’. However, this difference was not seen in ‘low-sensitizers’ (P = 0.651). Main effects for TCI-step, HADS-scores, and PCS-scores were not significantly different (<xref rid="pone.0242169.t005" ref-type="table">Table 5</xref>).</p>
                  <table-wrap id="pone.0242169.t004" orientation="portrait" position="float">
                    <object-id pub-id-type="doi">10.1371/journal.pone.0242169.t004</object-id>
                    <label>Table 4</label>
                    <caption>
                      <title>Mixed-effects model (secondary hyperalgesia area data).</title>
                    </caption>
                    <alternatives>
                      <graphic id="pone.0242169.t004g" xlink:href="pone.0242169.t004"/>
                      <table frame="hsides" rules="groups">
                        <colgroup span="1">
                          <col align="left" valign="middle" span="1"/>
                          <col align="left" valign="middle" span="1"/>
                          <col align="left" valign="middle" span="1"/>
                          <col align="left" valign="middle" span="1"/>
                        </colgroup>
                        <thead>
                          <tr>
                            <th align="left" colspan="2" rowspan="1">
                              <bold>Fixed-effect variable</bold>
                            </th>
                            <th align="left" rowspan="1" colspan="1">
                              <bold>Estimate (95% CI; cm<sup>2</sup>)</bold>
                            </th>
                            <th align="left" rowspan="1" colspan="1">
                              <bold>P-value</bold>
                            </th>
                          </tr>
                        </thead>
                        <tbody>
                          <tr>
                            <td align="justify" colspan="2" rowspan="1">
                              <bold>
                                <bold>Intercept</bold>
                              </bold>
                            </td>
                            <td align="justify" rowspan="1" colspan="1">36.1 (1.3–70.9)</td>
                            <td align="justify" rowspan="1" colspan="1">0.042</td>
                          </tr>
                          <tr>
                            <td align="justify" rowspan="1" colspan="1">
                              <bold>
                                <bold>Intervention</bold>
                              </bold>
                            </td>
                            <td align="justify" rowspan="1" colspan="1">Placebo</td>
                            <td align="justify" rowspan="1" colspan="1">-13.4 (-24.2–-2.6)</td>
                            <td align="justify" rowspan="1" colspan="1">0.015</td>
                          </tr>
                          <tr>
                            <td align="justify" rowspan="1" colspan="1"/>
                            <td align="justify" rowspan="1" colspan="1">Naloxone</td>
                            <td align="justify" rowspan="1" colspan="1">0</td>
                            <td align="justify" rowspan="1" colspan="1">-</td>
                          </tr>
                        </tbody>
                      </table>
                    </alternatives>
                    <table-wrap-foot>
                      <fn id="t004fn001">
                        <p>Secondary hyperalgesia area (SHA) data from the mixed-effects model with random effect for subject, and fixed effects for the variables ‘sensitizers’ (‘high-sensitizers’/’low-sensitizers’), intervention (naloxone/placebo), target-controlled infusion-step (step 1, 2, 3), Hospital Anxiety and Depression Scale scores, and Pain Catastrophizing Scale scores for the primary outcome SHA.</p>
                      </fn>
                    </table-wrap-foot>
                  </table-wrap>
                  <table-wrap id="pone.0242169.t005" orientation="portrait" position="float">
                    <object-id pub-id-type="doi">10.1371/journal.pone.0242169.t005</object-id>
                    <label>Table 5</label>
                    <caption>
                      <title>Post hoc mixed-effects model (secondary hyperalgesia area data).</title>
                    </caption>
                    <alternatives>
                      <graphic id="pone.0242169.t005g" xlink:href="pone.0242169.t005"/>
                      <table frame="hsides" rules="groups">
                        <colgroup span="1">
                          <col align="left" valign="middle" span="1"/>
                          <col align="left" valign="middle" span="1"/>
                          <col align="left" valign="middle" span="1"/>
                          <col align="left" valign="middle" span="1"/>
                        </colgroup>
                        <thead>
                          <tr>
                            <th align="justify" colspan="2" rowspan="1">
                              <bold>Fixed-effect variable</bold>
                            </th>
                            <th align="justify" rowspan="1" colspan="1">
                              <bold>Estimate (95% CI; cm<sup>2</sup>)</bold>
                            </th>
                            <th align="justify" rowspan="1" colspan="1">
                              <bold>P-value</bold>
                            </th>
                          </tr>
                        </thead>
                        <tbody>
                          <tr>
                            <td align="justify" rowspan="1" colspan="1">
                              <bold>
                                <bold>Intercept</bold>
                              </bold>
                            </td>
                            <td align="justify" rowspan="1" colspan="1"/>
                            <td align="justify" rowspan="1" colspan="1">46.6 (-3.5–96.8)</td>
                            <td align="justify" rowspan="1" colspan="1">0.068</td>
                          </tr>
                          <tr>
                            <td align="justify" rowspan="1" colspan="1">
                              <bold>
                                <bold>Intervention</bold>
                              </bold>
                            </td>
                            <td align="justify" rowspan="1" colspan="1">Placebo</td>
                            <td align="justify" rowspan="1" colspan="1">-35.4 (-49.8–-21.1)</td>
                            <td align="justify" rowspan="1" colspan="1">&lt; 0.001</td>
                          </tr>
                          <tr>
                            <td align="justify" rowspan="1" colspan="1"/>
                            <td align="justify" rowspan="1" colspan="1">Naloxone</td>
                            <td align="justify" rowspan="1" colspan="1">0</td>
                            <td align="justify" rowspan="1" colspan="1">-</td>
                          </tr>
                          <tr>
                            <td align="justify" rowspan="1" colspan="1">
                              <bold>
                                <bold>Sensitizers</bold>
                              </bold>
                            </td>
                            <td align="justify" rowspan="1" colspan="1">‘Low-sensitizers’</td>
                            <td align="justify" rowspan="1" colspan="1">-38.1 (-107.6–31.4)</td>
                            <td align="justify" rowspan="1" colspan="1">0.275</td>
                          </tr>
                          <tr>
                            <td align="justify" rowspan="1" colspan="1"/>
                            <td align="justify" rowspan="1" colspan="1">‘High-sensitizers’</td>
                            <td align="justify" rowspan="1" colspan="1">0</td>
                            <td align="justify" rowspan="1" colspan="1">-</td>
                          </tr>
                          <tr>
                            <td align="justify" rowspan="1" colspan="1">
                              <bold>
                                <bold>Time</bold>
                              </bold>
                            </td>
                            <td align="justify" rowspan="1" colspan="1">Session <bold>2</bold></td>
                            <td align="justify" rowspan="1" colspan="1">49.7 (35.4–64.1)</td>
                            <td align="justify" rowspan="1" colspan="1">&lt; 0.001</td>
                          </tr>
                          <tr>
                            <td align="justify" rowspan="1" colspan="1"/>
                            <td align="justify" rowspan="1" colspan="1">Session <bold>4</bold></td>
                            <td align="justify" rowspan="1" colspan="1">0</td>
                            <td align="justify" rowspan="1" colspan="1">-</td>
                          </tr>
                          <tr>
                            <td align="justify" rowspan="1" colspan="1">
                              <bold>
                                <bold>Intervention*’sensitizer’</bold>
                              </bold>
                            </td>
                            <td align="justify" rowspan="1" colspan="1">Placebo*’low-sensitizer’</td>
                            <td align="justify" rowspan="1" colspan="1">32.2 (12.3–52.2)</td>
                            <td align="justify" rowspan="1" colspan="1">0.002</td>
                          </tr>
                          <tr>
                            <td align="justify" rowspan="1" colspan="1"/>
                            <td align="justify" rowspan="1" colspan="1">Placebo*’high-sensitizer’</td>
                            <td align="justify" rowspan="1" colspan="1">0</td>
                            <td align="justify" rowspan="1" colspan="1">-</td>
                          </tr>
                          <tr>
                            <td align="justify" rowspan="1" colspan="1"/>
                            <td align="justify" rowspan="1" colspan="1">Naloxone*’low-sensitizer’</td>
                            <td align="justify" rowspan="1" colspan="1">0</td>
                            <td align="justify" rowspan="1" colspan="1">-</td>
                          </tr>
                          <tr>
                            <td align="justify" rowspan="1" colspan="1"/>
                            <td align="justify" rowspan="1" colspan="1">Naloxone*’high-sensitizer’</td>
                            <td align="justify" rowspan="1" colspan="1">0</td>
                            <td align="justify" rowspan="1" colspan="1">-</td>
                          </tr>
                          <tr>
                            <td align="justify" rowspan="1" colspan="1">
                              <bold>
                                <bold>‘Sensitizer’*time</bold>
                              </bold>
                            </td>
                            <td align="justify" rowspan="1" colspan="1">‘Low-sensitizer’*Session <bold>2</bold></td>
                            <td align="justify" rowspan="1" colspan="1">-48.7 (-68.6–-28.7)</td>
                            <td align="justify" rowspan="1" colspan="1">&lt; 0.001</td>
                          </tr>
                          <tr>
                            <td align="justify" rowspan="1" colspan="1"/>
                            <td align="justify" rowspan="1" colspan="1">‘Low-sensitizer’*Session <bold>4</bold></td>
                            <td align="justify" rowspan="1" colspan="1">0</td>
                            <td align="justify" rowspan="1" colspan="1">-</td>
                          </tr>
                          <tr>
                            <td align="justify" rowspan="1" colspan="1"/>
                            <td align="justify" rowspan="1" colspan="1">‘High-sensitizer’*Session <bold>2</bold></td>
                            <td align="justify" rowspan="1" colspan="1">0</td>
                            <td align="justify" rowspan="1" colspan="1">-</td>
                          </tr>
                          <tr>
                            <td align="justify" rowspan="1" colspan="1"/>
                            <td align="justify" rowspan="1" colspan="1">‘High-sensitizer’*Session <bold>4</bold></td>
                            <td align="justify" rowspan="1" colspan="1">0</td>
                            <td align="justify" rowspan="1" colspan="1">-</td>
                          </tr>
                        </tbody>
                      </table>
                    </alternatives>
                    <table-wrap-foot>
                      <fn id="t005fn001">
                        <p>Secondary hyperalgesia area (SHA) data from the mixed-effects model with random effect for subject and fixed effects for the variables ‘sensitizers’ (‘high-sensitizers’/’low-sensitizers’), intervention (naloxone/placebo), target-controlled infusion-step (step 1, 2, 3), time (Session <bold>2</bold>, <bold>4</bold>), Hospital Anxiety and Depression Scale scores and Pain Catastrophizing Scale scores for the primary outcome SHA.</p>
                      </fn>
                    </table-wrap-foot>
                  </table-wrap>
                  <table-wrap id="pone.0242169.t006" orientation="portrait" position="float">
                    <object-id pub-id-type="doi">10.1371/journal.pone.0242169.t006</object-id>
                    <label>Table 6</label>
                    <caption>
                      <title>Estimates of fixed effects for the mixed-effects model (secondary hyperalgesia area data).</title>
                    </caption>
                    <alternatives>
                      <graphic id="pone.0242169.t006g" xlink:href="pone.0242169.t006"/>
                      <table frame="hsides" rules="groups">
                        <colgroup span="1">
                          <col align="left" valign="middle" span="1"/>
                          <col align="left" valign="middle" span="1"/>
                          <col align="left" valign="middle" span="1"/>
                          <col align="left" valign="middle" span="1"/>
                        </colgroup>
                        <tbody>
                          <tr>
                            <td align="justify" colspan="2" rowspan="1">
                              <bold>
                                <bold>Fixed-effect variable</bold>
                              </bold>
                            </td>
                            <td align="justify" rowspan="1" colspan="1">
                              <bold>
                                <bold>Estimate (95% CI; cm</bold>
                                <sup>
                                  <bold>2</bold>
                                </sup>
                                <bold>)</bold>
                              </bold>
                            </td>
                            <td align="justify" rowspan="1" colspan="1">
                              <bold>
                                <bold>P-value</bold>
                              </bold>
                            </td>
                          </tr>
                          <tr>
                            <td align="justify" rowspan="1" colspan="1">
                              <bold>
                                <bold>‘High-sensitizers’</bold>
                              </bold>
                            </td>
                            <td align="justify" rowspan="1" colspan="1">Placebo</td>
                            <td align="justify" rowspan="1" colspan="1">-35.4 (-49.8–-21.1)</td>
                            <td align="justify" rowspan="1" colspan="1">&lt; 0.001</td>
                          </tr>
                          <tr>
                            <td align="justify" rowspan="1" colspan="1"/>
                            <td align="justify" rowspan="1" colspan="1">Naloxone</td>
                            <td align="justify" rowspan="1" colspan="1">0</td>
                            <td align="justify" rowspan="1" colspan="1">-</td>
                          </tr>
                          <tr>
                            <td align="justify" rowspan="1" colspan="1">
                              <bold>
                                <bold>‘Low-sensitizers’</bold>
                              </bold>
                            </td>
                            <td align="justify" rowspan="1" colspan="1">Placebo</td>
                            <td align="justify" rowspan="1" colspan="1">-3.2 (-17.1–10.7)</td>
                            <td align="justify" rowspan="1" colspan="1">0.651</td>
                          </tr>
                          <tr>
                            <td align="justify" rowspan="1" colspan="1"/>
                            <td align="justify" rowspan="1" colspan="1">Naloxone</td>
                            <td align="justify" rowspan="1" colspan="1">0</td>
                            <td align="justify" rowspan="1" colspan="1">-</td>
                          </tr>
                        </tbody>
                      </table>
                    </alternatives>
                    <table-wrap-foot>
                      <fn id="t006fn001">
                        <p>Estimated means of fixed effects from the mixed-effects model using secondary hyperalgesia area (SHA) data. Variables include ‘sensitizers’ and intervention.</p>
                      </fn>
                    </table-wrap-foot>
                  </table-wrap>
                </sec>
              </sec>
              <sec id="sec033">
                <title>Other outcomes</title>
                <sec id="sec034">
                  <title>Mechanical pain thresholds</title>
                  <p>There was no significant difference between PPTs in the area of primary hyperalgesia following naloxone (median [95% CI]: 0 [0–0]) compared to placebo (median [95% CI]: 0 [0–0]; Wilcoxon signed-rank test: P = 0.663) when correcting for baseline by using the difference between pre-infusion and post-infusion PPT values. Furthermore, no significant difference was seen for PPTs in the area of secondary hyperalgesia following naloxone (median [95% CI]: 0 [0–0]) compared to placebo (median [95% CI]: 0 [0–0]; Wilcoxon signed-rank test: P = 0.854).</p>
                </sec>
                <sec id="sec035">
                  <title>Pain during induction of the cutaneous heat injury</title>
                  <p>There was no significant difference in pain intensity during Session <bold>1</bold> (mean [95% CI]: 4.2 [3.6–4.8] NRS) compared to Session <bold>3</bold> (mean [95% CI]: 4.2 [3.6–4.8] NRS; Paired t test: P = 0.808). Almost perfect inter-session consistencies in pain intensity ratings were demonstrated between Sessions <bold>0</bold>, <bold>1</bold>, and <bold>3</bold> (ICC [95% CI] = 0.92 [0.86–0.96]). No significant difference in pain intensity was demonstrated between ‘high-sensitizers’ (mean [95% CI]: 4.5 [3.7–5.3]) and ‘low-sensitizers’ (mean [95% CI]: 3.9 [3.1–4.6] NRS; unpaired t test: -1.7–0.5, P = 0.263).</p>
                </sec>
                <sec id="sec036">
                  <title>Clinical opiate withdrawal scale</title>
                  <p>One subject (#AH39) had a COWS rating at step 2 during the naloxone infusion of 5 (1 at baseline), corresponding to mild opiate withdrawal symptoms. Symptoms included yawning, nausea, restlessness, and anxiousness. No other subjects experienced significant opiate withdrawal symptoms during the infusions.</p>
                </sec>
                <sec id="sec037">
                  <title>Psychometrics</title>
                  <p>No subject reached a cut-off score indicating anxiety (HADS-A; median [95% CI]: 3 [2 to 4]) or depressive behavior (HADS-D; 1 [1 to 2]). However, two subjects had a HADS-A score suggestive of an anxiety disorder (#AD03: HADS-A = 8, #AQ09: HADS-A = 9). No subject scored outside the normal range on the PCS score (median [95% CI]: 6 [<xref rid="pone.0242169.ref004" ref-type="bibr">4</xref>–<xref rid="pone.0242169.ref008" ref-type="bibr">8</xref>]).</p>
                </sec>
                <sec id="sec038">
                  <title>Online reaction time test</title>
                  <p>A two-way repeated-measures ANOVA showed no significant interaction between the effect of intervention and TCI-step on the reaction time (P = 0.615).</p>
                </sec>
              </sec>
              <sec id="sec039">
                <title>Adverse events</title>
                <p>For a detailed description of adverse events (AEs), see <xref ref-type="supplementary-material" rid="pone.0242169.s004">S1 Adverse</xref> events.</p>
                <sec id="sec040">
                  <title>Events related to the trial drug</title>
                  <p>Adverse events of mild intensity including tiredness, nausea, vomiting, dizziness, headache, itching, and restlessness were experienced by 22/38 subjects receiving naloxone compared to 4/38 subjects following placebo (Chi<sup>2</sup> test: P &lt; 0.001). One subject (#AH39) experienced moderate AEs, including anxiety, nausea, and dizziness. One subject (#AX25) experienced anxiety, dizziness, unilateral paresthesia of the arm and leg, and perioral numbness during the naloxone infusion. In both subjects the infusion was discontinued prematurely, but both agreed to further trial participation and were not excluded from the analysis.</p>
                </sec>
                <sec id="sec041">
                  <title>Events unrelated to the trial drug</title>
                  <p>One subject (#92) experienced a vasovagal syncope immediately following the CHI during Session <bold>0</bold> and was excluded from further participation in the trial (<xref ref-type="fig" rid="pone.0242169.g001">Fig 1</xref>). No blistering was observed following the CHIs.</p>
                </sec>
              </sec>
              <sec id="sec042">
                <title>Protocol violations</title>
                <p>Trial drug package #31 was opened unintentionally, and therefore the package was discarded.</p>
                <p>One subject (#43) had a body mass index of 30.7 kg/m<sup>2</sup> exceeding the predetermined upper margin of 30.0 kg/m<sup>2</sup>.</p>
                <p>The statistical analysis plan concerning the a priori mixed-effects model with random effects for subject was changed before the un-blinding of data. The trial statistician recommended adding the variable time (Session <bold>2</bold>, <bold>4</bold>) to the other fixed effects variables (cf. Materials and methods—Statistical analysis: ‘sensitizers’; intervention; TCI-step; HADS-scores, and PCS-scores), since time-dependent changes affecting the analyses were likely to occur.</p>
              </sec>
              <sec id="sec043">
                <title>Missing values</title>
                <p>One subject (#AH39) did not finish the online reaction time test in the last TCI-step due to naloxone-induced side effects. This subject was therefore excluded from the online reaction time analysis.</p>
              </sec>
            </sec>
            <sec sec-type="conclusions" id="sec044">
              <title>Discussion</title>
              <sec id="sec045">
                <title>Short summary</title>
                <p>In the present randomized, controlled, crossover trial, an enriched design was essential in separating sensory phenotypes based on a conditioning heat injury. While the late post-injury naloxone challenge, analyzed by univariate statistics, could not demonstrate reinstatement of latent sensitization, a multivariate mixed-effects model inferred that this could be the case in ‘high-sensitizer’ subjects.</p>
              </sec>
              <sec id="sec046">
                <title>Cutaneous heat injury model</title>
                <sec id="sec047">
                  <title>Previous studies</title>
                  <p>The CHI model is a reference model in human experimental pain, similarly to the ultraviolet-B (UVB) and capsaicin models [<xref rid="pone.0242169.ref032" ref-type="bibr">32</xref>]. In pharmacodynamical research, the CHI model has demonstrated moderate analgesic efficacy of ketamine [<xref rid="pone.0242169.ref033" ref-type="bibr">33</xref>–<xref rid="pone.0242169.ref036" ref-type="bibr">36</xref>] and opioids [<xref rid="pone.0242169.ref034" ref-type="bibr">34</xref>, <xref rid="pone.0242169.ref037" ref-type="bibr">37</xref>], but only limited efficacy of anti-inflammatory drugs [<xref rid="pone.0242169.ref038" ref-type="bibr">38</xref>–<xref rid="pone.0242169.ref040" ref-type="bibr">40</xref>], a paradox since the model is inflammatory in nature. The model, however, provides long-lasting hyperalgesia [<xref rid="pone.0242169.ref041" ref-type="bibr">41</xref>].</p>
                </sec>
                <sec id="sec048">
                  <title>Secondary hyperalgesia</title>
                  <p>Assessments of SHAs are regularly used as a quantitative outcome measure of central sensitization and has been used in physiological studies [<xref rid="pone.0242169.ref042" ref-type="bibr">42</xref>, <xref rid="pone.0242169.ref043" ref-type="bibr">43</xref>], clinical predictive studies [<xref rid="pone.0242169.ref044" ref-type="bibr">44</xref>], and pharmacodynamical studies [<xref rid="pone.0242169.ref019" ref-type="bibr">19</xref>, <xref rid="pone.0242169.ref035" ref-type="bibr">35</xref>, <xref rid="pone.0242169.ref045" ref-type="bibr">45</xref>]. Cutaneous heat injury-induced secondary hyperalgesia is a consistent and reproducible measure with low intra-subject variability [<xref rid="pone.0242169.ref020" ref-type="bibr">20</xref>, <xref rid="pone.0242169.ref046" ref-type="bibr">46</xref>]. Delineation of SHAs is made by punctate (pin-prick) stimulations, conventionally using polyamide monofilaments. However, a comparative trial between the weighted-pin instrument and monofilaments has indicated more reliable measurements, with less variance and larger magnitudes of SHAs with the former method [<xref rid="pone.0242169.ref020" ref-type="bibr">20</xref>].</p>
                  <p>The development of large SHAs has been revealed as a risk factor for developing chronic pain [<xref rid="pone.0242169.ref047" ref-type="bibr">47</xref>–<xref rid="pone.0242169.ref049" ref-type="bibr">49</xref>]. Further, physiological brain similarities exist between subjects with large SHAs following a CHI and chronic pain patients [<xref rid="pone.0242169.ref018" ref-type="bibr">18</xref>]. On the other hand, an association between SHAs and acute postoperative pain is not readily apparent [<xref rid="pone.0242169.ref050" ref-type="bibr">50</xref>–<xref rid="pone.0242169.ref052" ref-type="bibr">52</xref>]. Although subjects clearly show phenotypical differences in the development of SHAs, the importance of SHAs could not be definitively established in the present proof of concept trial, in terms of opioid receptor-masked latent sensitization.</p>
                </sec>
              </sec>
              <sec id="sec049">
                <title>Naloxone</title>
                <sec id="sec050">
                  <title>Comparative dose aspects</title>
                  <p>The present trial used a naloxone dose of 3.25 mg/kg, which is 600 to 6,000 times higher than the recommended clinical dose used in the treatment of a severe opioid overdose [<xref rid="pone.0242169.ref053" ref-type="bibr">53</xref>]. Animal studies have unmasked latent sensitization with 0.3–10 mg/kg of naloxone [<xref rid="pone.0242169.ref005" ref-type="bibr">5</xref>, <xref rid="pone.0242169.ref014" ref-type="bibr">14</xref>] or 3 mg/kg of naltrexone [<xref rid="pone.0242169.ref011" ref-type="bibr">11</xref>, <xref rid="pone.0242169.ref012" ref-type="bibr">12</xref>]. Uncorroborated data from a positron emission tomography (PET) trial indicated that administration of 0.1 mg/kg of naloxone completely inhibited the binding of [<sup>11</sup>C]-carfentanil to MOR receptors [<xref rid="pone.0242169.ref054" ref-type="bibr">54</xref>]. Given that the naloxone dose in the present trial by far exceeds 0.1 mg/kg, an unknown ‘off-target’ effect of the drug is not unlikely.</p>
                </sec>
                <sec id="sec051">
                  <title>Adverse events</title>
                  <p>Previous studies have shown that systemic doses up to 6.0 mg/kg have been tolerated well in healthy participants [<xref rid="pone.0242169.ref055" ref-type="bibr">55</xref>–<xref rid="pone.0242169.ref060" ref-type="bibr">60</xref>], and even with higher doses in patients [<xref rid="pone.0242169.ref061" ref-type="bibr">61</xref>–<xref rid="pone.0242169.ref066" ref-type="bibr">66</xref>] with none or only mild to moderate AEs. However, AEs have not been systematically examined in any of these trials. In our previous trial, six out of 15 subjects reported mild AEs, including tiredness, epigastric pain, frontal headache, and photophobia, but no serious adverse events were observed [<xref rid="pone.0242169.ref014" ref-type="bibr">14</xref>]. Similar AEs were observed in the present 38 subjects (cf. Results—Adverse events). Based on these findings, no safety issues regarding the current naloxone dosing have been demonstrated.</p>
                </sec>
                <sec id="sec052">
                  <title>Pharmacokinetics</title>
                  <p>We recently evaluated our three-stage stepwise infusion-algorithm in an exploratory pharmacokinetic study in healthy volunteers (n = 8), where we showed that the naloxone plasma concentrations estimated from the population-kinetic modelling were approximately 3-fold higher than the observed [<xref rid="pone.0242169.ref067" ref-type="bibr">67</xref>]. However, the observed peak plasma concentrations of naloxone and naloxone-3-glucuronide in the eight volunteers [<xref rid="pone.0242169.ref067" ref-type="bibr">67</xref>] were more than 30 times higher than seen in previously published studies [<xref rid="pone.0242169.ref021" ref-type="bibr">21</xref>, <xref rid="pone.0242169.ref068" ref-type="bibr">68</xref>, <xref rid="pone.0242169.ref069" ref-type="bibr">69</xref>] and were of the same magnitude (1000 mg/mL) as in the study by Pereira et al. [<xref rid="pone.0242169.ref022" ref-type="bibr">22</xref>].</p>
                </sec>
              </sec>
              <sec id="sec053">
                <title>Data interpretation</title>
                <p>For statistical and methodological reasons, we could not unequivocally demonstrate a statistically significant unmasking effect of naloxone on latent sensitization in the CHI model.</p>
                <p>First, univariate and multivariate statistical methods yielded different outcomes. While univariate comparisons did not demonstrate a significant difference between infusion treatments or groups, the post hoc mixed-effects model (including the variable time [cf. Materials and methods—Statistical analysis]) yielded a highly significant effect of naloxone on SHAs in the ‘high-sensitizers’. No outlier analysis was stipulated in the protocol, but simple visual inspection of the data reveals high data heterogeneity that may have inferred statistical errors (<xref ref-type="fig" rid="pone.0242169.g006">Fig 6</xref>). However, the assigned P-value 0.01 was targeted at mitigating type 1 errors. In the mixed-effect model, a highly significant interaction between ‘sensitizers’*time was observed, indicating that not only sensitizer affiliation, but also the time of injection (Session <bold>2</bold> or <bold>4</bold>) seemed to affect the SHA outcome. We have no definitive explanation for this possible time effect, but likely it is caused by data outliers.</p>
                <p>Second, the current and previous human trials investigating the phenomenon of latent sensitization have been restricted to the use of MOR inverse agonists. By contrast, pre-clinical research suggests that several pain inhibitory G-protein coupled receptors, including μ- δ- and κ-opioid receptors, α<sub>2A</sub>-adrenergic receptors, and neuropeptide Y1 and Y2 receptors all contribute to the masking of latent sensitization [<xref rid="pone.0242169.ref005" ref-type="bibr">5</xref>, <xref rid="pone.0242169.ref011" ref-type="bibr">11</xref>, <xref rid="pone.0242169.ref012" ref-type="bibr">12</xref>, <xref rid="pone.0242169.ref070" ref-type="bibr">70</xref>–<xref rid="pone.0242169.ref073" ref-type="bibr">73</xref>]. This raises the question as to whether the mechanisms involved in latent sensitization differ between species, or whether blockade of just opioid receptors is not sufficient to reveal latent sensitization in humans. Indeed, receptor interactions include a 100-fold synergy between endogenous μ-opioid and neuropeptide Y1 receptors [<xref rid="pone.0242169.ref074" ref-type="bibr">74</xref>], leading us to speculate that perhaps a balanced mixture of drugs will be required to reveal latent sensitization in humans.</p>
                <p>Third, the conditioning tissue injury used in the present trial, putatively leading to latent sensitization, only covered a fraction of the body surface area (&lt; 0.1%), and only involved a relatively weak inflammatory response, that may have been insufficient to trigger the development of latent sensitization. The CHI model has been back translated to the mouse hind paw (52°C, 40 s). Three weeks later, naloxone dose-dependently reinstated hyperalgesia in these mice. However, the injury was applied to weight-bearing glabrous skin covering a much larger fractional area [<xref rid="pone.0242169.ref075" ref-type="bibr">75</xref>] than in humans. The issue of the limited injury in the present trial could be overcome by studying surgical models with higher severity of tissue injury, e.g., impacted mandibular third molar extraction or groin hernia repair.</p>
                <p>Fourth, an issue in previous mouse studies could be a selection bias. The inbred C57BL/6J mouse strain, used in earlier latent sensitization research [<xref rid="pone.0242169.ref011" ref-type="bibr">11</xref>, <xref rid="pone.0242169.ref012" ref-type="bibr">12</xref>], exhibits markedly enhanced pain sensitivity and thus can be considered belonging to a ‘high-sensitizer’ clone [<xref rid="pone.0242169.ref076" ref-type="bibr">76</xref>–<xref rid="pone.0242169.ref078" ref-type="bibr">78</xref>]. However, latent sensitization is readily observed in the outbred Sprague-Dawley rat [<xref rid="pone.0242169.ref012" ref-type="bibr">12</xref>].</p>
                <p>Addressing some of the above-mentioned issues may accommodate future trials. Nevertheless, the pathophysiological role of latent sensitization in development of chronic pain is speculative. Albeit, if the unmasking of latent sensitization proves to be an essential element of the postsurgical chronification process, it may improve our understanding of the mechanisms involved significantly. This may lead to targeted presurgical, preventive interventions, but also to novel management strategies in established postsurgical pain states.</p>
              </sec>
              <sec id="sec054">
                <title>Limitations</title>
                <sec id="sec055">
                  <title>Data variability</title>
                  <p>The sample size estimates were based on a previous high-dose naloxone trial involving 12 subjects rendering three subjects in each quartile of ‘high-sensitizers’ and ‘low-sensitizers’ (cf. Materials and methods—Sample size calculation) [<xref rid="pone.0242169.ref014" ref-type="bibr">14</xref>]. Data from this low-powered trial obviously lead to fragile estimations of sample size. Other important statistical aspects are discussed above.</p>
                </sec>
                <sec id="sec056">
                  <title>Effects during placebo treatment</title>
                  <p>The assessments during the placebo infusion yielded substantial SHAs corroborating findings from a previous naloxone trial [<xref rid="pone.0242169.ref013" ref-type="bibr">13</xref>]. Two explanations are possible. First, residual sensitizing effects of the preceding CHI 168 h earlier, enhanced by repeated pin-prick stimuli [<xref rid="pone.0242169.ref041" ref-type="bibr">41</xref>], may occur in susceptible subjects. Second, a ‘classic’ placebo response may potentially alter the magnitude of secondary hyperalgesia [<xref rid="pone.0242169.ref079" ref-type="bibr">79</xref>]: including subjects’ knowledge of the expected dose-dependent effect, and an auditory awareness of changes in the pump infusion rate.</p>
                </sec>
              </sec>
              <sec id="sec057">
                <title>Strengths</title>
                <sec id="sec058">
                  <title>Trial sample</title>
                  <p>Only healthy young male subjects were included in the trial, providing a very homogenous sample group. Only two subjects were excluded after Session <bold>0</bold>, and missing data were negligible.</p>
                </sec>
                <sec id="sec059">
                  <title>Enrichment design</title>
                  <p>A moderate to substantial agreement between the CHI-sessions was observed regarding the SHAs similar to previous observations [<xref rid="pone.0242169.ref017" ref-type="bibr">17</xref>, <xref rid="pone.0242169.ref046" ref-type="bibr">46</xref>]. However, there was a significant difference in SHAs between Session <bold>0</bold> and Session <bold>1</bold> for the ‘low-sensitizers’, which may have been caused by the use of different sites for the CHI across the two sessions (thigh vs. medial calf).</p>
                </sec>
              </sec>
              <sec id="sec060" sec-type="materials|methods">
                <title>Methods</title>
                <p>Two proficient investigators (ASD, EKJ) carried out all assessments. To reduce carry-over effects between CHI-sessions, contralateral mirror sites were used, including a ‘recovery’ period ≥ 41 days between the sessions. The sensory equipment used for the CHIs were regularly calibrated.</p>
              </sec>
            </sec>
            <sec sec-type="conclusions" id="sec061">
              <title>Conclusion</title>
              <p>The trial examined naloxone-induced reinstatement of latent sensitization in a cutaneous heat injury model in healthy males. The results could not unequivocally establish the phenomenon of latent sensitization in humans. While latent sensitization may occur in humans, it is not as prevalent a finding as in rodents. Further trials, including postsurgical pain models are needed to prove the clinical significance of latent sensitization and its opposing endogenous analgesia.</p>
            </sec>
            <sec sec-type="supplementary-material" id="sec062">
              <title>Supporting information</title>
              <supplementary-material content-type="local-data" id="pone.0242169.s001">
                <label>S1 Checklist</label>
                <caption>
                  <title>CONSORT 2010 checklist.</title>
                  <p>(DOC)</p>
                </caption>
                <media xlink:href="pone.0242169.s001.doc">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material content-type="local-data" id="pone.0242169.s002">
                <label>S1 Table</label>
                <caption>
                  <title>Trial data.</title>
                  <p>Table with individual data on demographics, sensitizer allocation, psychometrics (HADS and PCS), secondary hyperalgesia areas in relation to the cutaneous heat injuries and during the target-controlled infusions, VAS pain scores, mechanical pain thresholds, and online reaction times.</p>
                  <p>(XLSX)</p>
                </caption>
                <media xlink:href="pone.0242169.s002.xlsx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material content-type="local-data" id="pone.0242169.s003">
                <label>S1 Protocol</label>
                <caption>
                  <title>Protocol.</title>
                  <p>(PDF)</p>
                </caption>
                <media xlink:href="pone.0242169.s003.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material content-type="local-data" id="pone.0242169.s004">
                <label>S1 Adverse events</label>
                <caption>
                  <title>Adverse events during the trial.</title>
                  <p>(DOCX)</p>
                </caption>
                <media xlink:href="pone.0242169.s004.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ack>
              <p>The authors gratefully acknowledge the practical assistance of Emilie Koldborg Jensen, M.B. and Louise Dorothea Skovbjerg, M.B., Neuroscience Center, Copenhagen University Hospitals, Denmark.</p>
            </ack>
            <ref-list>
              <title>References</title>
              <ref id="pone.0242169.ref001">
                <label>1</label>
                <mixed-citation publication-type="journal"><name><surname>Pielsticker</surname><given-names>A</given-names></name>, <name><surname>Haag</surname><given-names>G</given-names></name>, <name><surname>Zaudig</surname><given-names>M</given-names></name>, <name><surname>Lautenbacher</surname><given-names>S</given-names></name>. <article-title>Impairment of pain inhibition in chronic tension-type headache</article-title>. <source>Pain</source>. <year>2005</year>;<volume>118</volume>(<issue>1–2</issue>):<fpage>215</fpage>–<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1016/j.pain.2005.08.019</pub-id> .<?supplied-pmid 16202520?><pub-id pub-id-type="pmid">16202520</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0242169.ref002">
                <label>2</label>
                <mixed-citation publication-type="journal"><name><surname>Price</surname><given-names>DD</given-names></name>, <name><surname>Staud</surname><given-names>R</given-names></name>, <name><surname>Robinson</surname><given-names>ME</given-names></name>, <name><surname>Mauderli</surname><given-names>AP</given-names></name>, <name><surname>Cannon</surname><given-names>R</given-names></name>, <name><surname>Vierck</surname><given-names>CJ</given-names></name>. <article-title>Enhanced temporal summation of second pain and its central modulation in fibromyalgia patients</article-title>. <source>Pain</source>. <year>2002</year>;<volume>99</volume>(<issue>1–2</issue>):<fpage>49</fpage>–<lpage>59</lpage>. <pub-id pub-id-type="doi">10.1016/s0304-3959(02)00053-2</pub-id> .<?supplied-pmid 12237183?><pub-id pub-id-type="pmid">12237183</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0242169.ref003">
                <label>3</label>
                <mixed-citation publication-type="journal"><name><surname>Staud</surname><given-names>R</given-names></name>, <name><surname>Weyl</surname><given-names>EE</given-names></name>, <name><surname>Price</surname><given-names>DD</given-names></name>, <name><surname>Robinson</surname><given-names>ME</given-names></name>. <article-title>Mechanical and heat hyperalgesia highly predict clinical pain intensity in patients with chronic musculoskeletal pain syndromes</article-title>. <source>J Pain</source>. <year>2012</year>;<volume>13</volume>(<issue>8</issue>):<fpage>725</fpage>–<lpage>35</lpage>. <pub-id pub-id-type="doi">10.1016/j.jpain.2012.04.006</pub-id>
<?supplied-pmid 22739051?><pub-id pub-id-type="pmid">22739051</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0242169.ref004">
                <label>4</label>
                <mixed-citation publication-type="journal"><name><surname>Arendt-Nielsen</surname><given-names>L</given-names></name>, <name><surname>Morlion</surname><given-names>B</given-names></name>, <name><surname>Perrot</surname><given-names>S</given-names></name>, <name><surname>Dahan</surname><given-names>A</given-names></name>, <name><surname>Dickenson</surname><given-names>A</given-names></name>, <name><surname>Kress</surname><given-names>HG</given-names></name>, <etal>et al</etal><article-title>Assessment and manifestation of central sensitisation across different chronic pain conditions</article-title>. <source>Eur J Pain</source>. <year>2018</year>;<volume>22</volume>(<issue>2</issue>):<fpage>216</fpage>–<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1002/ejp.1140</pub-id> .<?supplied-pmid 29105941?><pub-id pub-id-type="pmid">29105941</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0242169.ref005">
                <label>5</label>
                <mixed-citation publication-type="journal"><name><surname>Campillo</surname><given-names>A</given-names></name>, <name><surname>Cabanero</surname><given-names>D</given-names></name>, <name><surname>Romero</surname><given-names>A</given-names></name>, <name><surname>Garcia-Nogales</surname><given-names>P</given-names></name>, <name><surname>Puig</surname><given-names>MM</given-names></name>. <article-title>Delayed postoperative latent pain sensitization revealed by the systemic administration of opioid antagonists in mice</article-title>. <source>Eur J Pharmacol</source>. <year>2011</year>;<volume>657</volume>(<issue>1–3</issue>):<fpage>89</fpage>–<lpage>96</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejphar.2011.01.059</pub-id> .<?supplied-pmid 21300053?><pub-id pub-id-type="pmid">21300053</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0242169.ref006">
                <label>6</label>
                <mixed-citation publication-type="journal"><name><surname>Taylor</surname><given-names>BK</given-names></name>, <name><surname>Corder</surname><given-names>G</given-names></name>. <article-title>Endogenous analgesia, dependence, and latent pain sensitization</article-title>. <source>Curr Top Behav Neurosci</source>. <year>2014</year>;<volume>20</volume>:<fpage>283</fpage>–<lpage>325</lpage>. <pub-id pub-id-type="doi">10.1007/7854_2014_351</pub-id>
<?supplied-pmid 25227929?><pub-id pub-id-type="pmid">25227929</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0242169.ref007">
                <label>7</label>
                <mixed-citation publication-type="journal"><name><surname>Rivat</surname><given-names>C</given-names></name>, <name><surname>Laboureyras</surname><given-names>E</given-names></name>, <name><surname>Laulin</surname><given-names>JP</given-names></name>, <name><surname>Le Roy</surname><given-names>C</given-names></name>, <name><surname>Richebe</surname><given-names>P</given-names></name>, <name><surname>Simonnet</surname><given-names>G</given-names></name>. <article-title>Non-nociceptive environmental stress induces hyperalgesia, not analgesia, in pain and opioid-experienced rats</article-title>. <source>Neuropsychopharmacology</source>. <year>2007</year>;<volume>32</volume>(<issue>10</issue>):<fpage>2217</fpage>–<lpage>28</lpage>. <pub-id pub-id-type="doi">10.1038/sj.npp.1301340</pub-id> .<?supplied-pmid 17299508?><pub-id pub-id-type="pmid">17299508</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0242169.ref008">
                <label>8</label>
                <mixed-citation publication-type="journal"><name><surname>Koppert</surname><given-names>W</given-names></name>, <name><surname>Filitz</surname><given-names>J</given-names></name>, <name><surname>Troster</surname><given-names>A</given-names></name>, <name><surname>Ihmsen</surname><given-names>H</given-names></name>, <name><surname>Angst</surname><given-names>M</given-names></name>, <name><surname>Flor</surname><given-names>H</given-names></name>, <etal>et al</etal><article-title>Activation of naloxone-sensitive and -insensitive inhibitory systems in a human pain model</article-title>. <source>J Pain</source>. <year>2005</year>;<volume>6</volume>(<issue>11</issue>):<fpage>757</fpage>–<lpage>64</lpage>. <pub-id pub-id-type="doi">10.1016/j.jpain.2005.07.002</pub-id> .<?supplied-pmid 16275600?><pub-id pub-id-type="pmid">16275600</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0242169.ref009">
                <label>9</label>
                <mixed-citation publication-type="journal"><name><surname>Werner</surname><given-names>MU</given-names></name>, <name><surname>Pereira</surname><given-names>MP</given-names></name>, <name><surname>Andersen</surname><given-names>LP</given-names></name>, <name><surname>Dahl</surname><given-names>JB</given-names></name>. <article-title>Endogenous opioid antagonism in physiological experimental pain models: a systematic review</article-title>. <source>PLoS One</source>. <year>2015</year>;<volume>10</volume>(<issue>6</issue>):<fpage>e0125887</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0125887</pub-id><?supplied-pmid 26029906?><pub-id pub-id-type="pmid">26029906</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0242169.ref010">
                <label>10</label>
                <mixed-citation publication-type="journal"><name><surname>Brennum</surname><given-names>J</given-names></name>, <name><surname>Kaiser</surname><given-names>F</given-names></name>, <name><surname>Dahl</surname><given-names>JB</given-names></name>. <article-title>Effect of naloxone on primary and secondary hyperalgesia induced by the human burn injury model</article-title>. <source>Acta Anaesthesiol Scand</source>. <year>2001</year>;<volume>45</volume>(<issue>8</issue>):<fpage>954</fpage>–<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1034/j.1399-6576.2001.450806.x</pub-id> .<?supplied-pmid 11576045?><pub-id pub-id-type="pmid">11576045</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0242169.ref011">
                <label>11</label>
                <mixed-citation publication-type="journal"><name><surname>Corder</surname><given-names>G</given-names></name>, <name><surname>Doolen</surname><given-names>S</given-names></name>, <name><surname>Donahue</surname><given-names>RR</given-names></name>, <name><surname>Winter</surname><given-names>MK</given-names></name>, <name><surname>Jutras</surname><given-names>BL</given-names></name>, <name><surname>He</surname><given-names>Y</given-names></name>, <etal>et al</etal><article-title>Constitutive mu-opioid receptor activity leads to long-term endogenous analgesia and dependence</article-title>. <source>Science</source>. <year>2013</year>;<volume>341</volume>(<issue>6152</issue>):<fpage>1394</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1126/science.1239403</pub-id>
<?supplied-pmid 24052307?><pub-id pub-id-type="pmid">24052307</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0242169.ref012">
                <label>12</label>
                <mixed-citation publication-type="journal"><name><surname>Walwyn</surname><given-names>WM</given-names></name>, <name><surname>Chen</surname><given-names>W</given-names></name>, <name><surname>Kim</surname><given-names>H</given-names></name>, <name><surname>Minasyan</surname><given-names>A</given-names></name>, <name><surname>Ennes</surname><given-names>HS</given-names></name>, <name><surname>McRoberts</surname><given-names>JA</given-names></name>, <etal>et al</etal><article-title>Sustained Suppression of Hyperalgesia during Latent Sensitization by mu-, delta-, and kappa-opioid receptors and alpha2A Adrenergic Receptors: Role of Constitutive Activity</article-title>. <source>J Neurosci</source>. <year>2016</year>;<volume>36</volume>(<issue>1</issue>):<fpage>204</fpage>–<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.1751-15.2016</pub-id>
<?supplied-pmid 26740662?><pub-id pub-id-type="pmid">26740662</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0242169.ref013">
                <label>13</label>
                <mixed-citation publication-type="journal"><name><surname>Pereira</surname><given-names>MP</given-names></name>, <name><surname>Werner</surname><given-names>MU</given-names></name>, <name><surname>Ringsted</surname><given-names>TK</given-names></name>, <name><surname>Rowbotham</surname><given-names>MC</given-names></name>, <name><surname>Taylor</surname><given-names>BK</given-names></name>, <name><surname>Dahl</surname><given-names>JB</given-names></name>. <article-title>Does naloxone reinstate secondary hyperalgesia in humans after resolution of a burn injury? A placebo-controlled, double-blind, randomized, cross-over study</article-title>. <source>PLoS One</source>. <year>2013</year>;<volume>8</volume>(<issue>5</issue>):<fpage>e64608</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0064608</pub-id><?supplied-pmid 23741350?><pub-id pub-id-type="pmid">23741350</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0242169.ref014">
                <label>14</label>
                <mixed-citation publication-type="journal"><name><surname>Pereira</surname><given-names>MP</given-names></name>, <name><surname>Donahue</surname><given-names>RR</given-names></name>, <name><surname>Dahl</surname><given-names>JB</given-names></name>, <name><surname>Werner</surname><given-names>M</given-names></name>, <name><surname>Taylor</surname><given-names>BK</given-names></name>, <name><surname>Werner</surname><given-names>MU</given-names></name>. <article-title>Endogenous Opioid-Masked Latent Pain Sensitization: Studies from Mouse to Human</article-title>. <source>PLoS One</source>. <year>2015</year>;<volume>10</volume>(<issue>8</issue>):<fpage>e0134441</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0134441</pub-id><?supplied-pmid 26305798?><pub-id pub-id-type="pmid">26305798</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0242169.ref015">
                <label>15</label>
                <mixed-citation publication-type="journal"><name><surname>McArthur</surname><given-names>SL</given-names></name>. <article-title>Repeatability, Reproducibility, and Replicability: Tackling the 3R challenge in biointerface science and engineering</article-title>. <source>Biointerphases</source>. <year>2019</year>;<volume>14</volume>(<issue>2</issue>):<fpage>020201</fpage><pub-id pub-id-type="doi">10.1116/1.5093621</pub-id> .<?supplied-pmid 30845806?><pub-id pub-id-type="pmid">30845806</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0242169.ref016">
                <label>16</label>
                <mixed-citation publication-type="journal"><name><surname>Springborg</surname><given-names>AD</given-names></name>, <name><surname>Jensen</surname><given-names>EK</given-names></name>, <name><surname>Taylor</surname><given-names>BK</given-names></name>, <name><surname>Werner</surname><given-names>MU</given-names></name>. <article-title>Effects of target-controlled infusion of high-dose naloxone on pain and hyperalgesia in a human thermal injury model: a study protocol: A randomized, double-blind, placebo-controlled, crossover trial with an enriched design</article-title>. <source>Medicine (Baltimore)</source>. <year>2016</year>;<volume>95</volume>(<issue>46</issue>):<fpage>e5336</fpage><pub-id pub-id-type="doi">10.1097/md.0000000000005336</pub-id><?supplied-pmid 27861362?><pub-id pub-id-type="pmid">27861362</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0242169.ref017">
                <label>17</label>
                <mixed-citation publication-type="journal"><name><surname>Ravn</surname><given-names>P</given-names></name>, <name><surname>Frederiksen</surname><given-names>R</given-names></name>, <name><surname>Skovsen</surname><given-names>AP</given-names></name>, <name><surname>Christrup</surname><given-names>LL</given-names></name>, <name><surname>Werner</surname><given-names>MU</given-names></name>. <article-title>Prediction of pain sensitivity in healthy volunteers</article-title>. <source>J Pain Res</source>. <year>2012</year>;<volume>5</volume>:<fpage>313</fpage>–<lpage>26</lpage>. <pub-id pub-id-type="doi">10.2147/JPR.S33925</pub-id> .<?supplied-pmid 23055774?><pub-id pub-id-type="pmid">23055774</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0242169.ref018">
                <label>18</label>
                <mixed-citation publication-type="journal"><name><surname>Asghar</surname><given-names>MS</given-names></name>, <name><surname>Pereira</surname><given-names>MP</given-names></name>, <name><surname>Werner</surname><given-names>MU</given-names></name>, <name><surname>Martensson</surname><given-names>J</given-names></name>, <name><surname>Larsson</surname><given-names>HBW</given-names></name>, <name><surname>Dahl</surname><given-names>JB</given-names></name>. <article-title>Secondary hyperalgesia phenotypes exhibit differences in brain activation during noxious stimulation</article-title>. <source>PLoS One</source>. <year>2015</year>;<volume>10</volume>(<issue>1</issue>):<fpage>e0114840</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0114840</pub-id> .<?supplied-pmid 25615578?><pub-id pub-id-type="pmid">25615578</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0242169.ref019">
                <label>19</label>
                <mixed-citation publication-type="journal"><name><surname>Andersen</surname><given-names>LP</given-names></name>, <name><surname>Gogenur</surname><given-names>I</given-names></name>, <name><surname>Fenger</surname><given-names>AQ</given-names></name>, <name><surname>Petersen</surname><given-names>MC</given-names></name>, <name><surname>Rosenberg</surname><given-names>J</given-names></name>, <name><surname>Werner</surname><given-names>MU</given-names></name>. <article-title>Analgesic and antihyperalgesic effects of melatonin in a human inflammatory pain model: a randomized, double-blind, placebo-controlled, three-arm crossover study</article-title>. <source>Pain</source>. <year>2015</year>;<volume>156</volume>(<issue>11</issue>):<fpage>2286</fpage>–<lpage>94</lpage>. <pub-id pub-id-type="doi">10.1097/j.pain.0000000000000284</pub-id> .<?supplied-pmid 26164585?><pub-id pub-id-type="pmid">26164585</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0242169.ref020">
                <label>20</label>
                <mixed-citation publication-type="journal"><name><surname>Ringsted</surname><given-names>TK</given-names></name>, <name><surname>Enghuus</surname><given-names>C</given-names></name>, <name><surname>Petersen</surname><given-names>MA</given-names></name>, <name><surname>Werner</surname><given-names>MU</given-names></name>. <article-title>Demarcation of secondary hyperalgesia zones: Punctate stimulation pressure matters</article-title>. <source>J Neurosci Methods</source>. <year>2015</year>;<volume>256</volume>:<fpage>74</fpage>–<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1016/j.jneumeth.2015.08.018</pub-id> .<?supplied-pmid 26310180?><pub-id pub-id-type="pmid">26310180</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0242169.ref021">
                <label>21</label>
                <mixed-citation publication-type="journal"><name><surname>Dowling</surname><given-names>J</given-names></name>, <name><surname>Isbister</surname><given-names>GK</given-names></name>, <name><surname>Kirkpatrick</surname><given-names>CM</given-names></name>, <name><surname>Naidoo</surname><given-names>D</given-names></name>, <name><surname>Graudins</surname><given-names>A</given-names></name>. <article-title>Population pharmacokinetics of intravenous, intramuscular, and intranasal naloxone in human volunteers</article-title>. <source>Ther Drug Monit</source>. <year>2008</year>;<volume>30</volume>(<issue>4</issue>):<fpage>490</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1097/FTD.0b013e3181816214</pub-id> .<?supplied-pmid 18641540?><pub-id pub-id-type="pmid">18641540</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0242169.ref022">
                <label>22</label>
                <mixed-citation publication-type="journal"><name><surname>Pereira</surname><given-names>MP</given-names></name>, <name><surname>Werner</surname><given-names>MU</given-names></name>, <name><surname>Dahl</surname><given-names>JB</given-names></name>. <article-title>Effect of a high-dose target-controlled naloxone infusion on pain and hyperalgesia in patients following groin hernia repair: study protocol for a randomized controlled trial</article-title>. <source>Trials</source>. <year>2015</year>;<volume>16</volume>:<fpage>511</fpage><pub-id pub-id-type="doi">10.1186/s13063-015-1021-6</pub-id><?supplied-pmid 26554360?><pub-id pub-id-type="pmid">26554360</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0242169.ref023">
                <label>23</label>
                <mixed-citation publication-type="journal"><name><surname>Dixon</surname><given-names>WJ</given-names></name>. <article-title>Staircase bioassay: the up-and-down method</article-title>. <source>Neurosci Biobehav Rev</source>. <year>1991</year>;<volume>15</volume>(<issue>1</issue>):<fpage>47</fpage>–<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1016/s0149-7634(05)80090-9</pub-id> .<?supplied-pmid 2052197?><pub-id pub-id-type="pmid">2052197</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0242169.ref024">
                <label>24</label>
                <mixed-citation publication-type="journal"><name><surname>Dixon</surname><given-names>WJ</given-names></name>. <article-title>The Up-and-Down Method for Small Samples</article-title>. <source>J Am Stat Assoc</source>. <year>1965</year>;<volume>60</volume>(<issue>312</issue>):<fpage>967</fpage>–<lpage>78</lpage>. <pub-id pub-id-type="doi">10.2307/2283398</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0242169.ref025">
                <label>25</label>
                <mixed-citation publication-type="journal"><name><surname>Wesson</surname><given-names>DR</given-names></name>, <name><surname>Ling</surname><given-names>W</given-names></name>. <article-title>The Clinical Opiate Withdrawal Scale (COWS)</article-title>. <source>J Psychoactive Drugs</source>. <year>2003</year>;<volume>35</volume>(<issue>2</issue>):<fpage>253</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1080/02791072.2003.10400007</pub-id> .<?supplied-pmid 12924748?><pub-id pub-id-type="pmid">12924748</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0242169.ref026">
                <label>26</label>
                <mixed-citation publication-type="journal"><name><surname>Snaith</surname><given-names>RP</given-names></name>. <article-title>The Hospital Anxiety And Depression Scale</article-title>. <source>Health Qual Life Outcomes</source>. <year>2003</year>;<volume>1</volume>:<fpage>29</fpage><pub-id pub-id-type="doi">10.1186/1477-7525-1-29</pub-id><?supplied-pmid 12914662?><pub-id pub-id-type="pmid">12914662</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0242169.ref027">
                <label>27</label>
                <mixed-citation publication-type="journal"><name><surname>Zigmond</surname><given-names>AS</given-names></name>, <name><surname>Snaith</surname><given-names>RP</given-names></name>. <article-title>The hospital anxiety and depression scale</article-title>. <source>Acta Psychiatr Scand</source>. <year>1983</year>;<volume>67</volume>(<issue>6</issue>):<fpage>361</fpage>–<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1111/j.1600-0447.1983.tb09716.x</pub-id> .<?supplied-pmid 6880820?><pub-id pub-id-type="pmid">6880820</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0242169.ref028">
                <label>28</label>
                <mixed-citation publication-type="journal"><name><surname>Sullivan</surname><given-names>MJL</given-names></name>, <name><surname>Bishop</surname><given-names>SR</given-names></name>, <name><surname>Pivik</surname><given-names>J</given-names></name>. <article-title>The Pain Catastrophizing Scale: Development and validation</article-title>. <source>Psychol Assess</source>. <year>1995</year>;<volume>7</volume>(<issue>4</issue>):<fpage>524</fpage>–<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1037/1040-3590.7.4.524</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0242169.ref029">
                <label>29</label>
                <mixed-citation publication-type="book"><name><surname>Sullivan</surname><given-names>MJL</given-names></name>. <source>The Pain Catastrophizing Scale User Manual</source> [Internet]. <publisher-loc>Montreal</publisher-loc>: <publisher-name>McGill University</publisher-name>; <year>2009</year> [cited 2016 September 30]. Available from: <ext-link ext-link-type="uri" xlink:href="https://sullivan-painresearch.mcgill.ca/pdf/pcs/PCSManual_English.pdf">https://sullivan-painresearch.mcgill.ca/pdf/pcs/PCSManual_English.pdf</ext-link>.</mixed-citation>
              </ref>
              <ref id="pone.0242169.ref030">
                <label>30</label>
                <mixed-citation publication-type="journal"><name><surname>Allen</surname><given-names>J</given-names></name>. <source>The Online Reaction Time Test</source> [Internet]; <year>2002</year> [cited 2016 September 30]. Available from: <ext-link ext-link-type="uri" xlink:href="https://faculty.washington.edu/chudler/java/redgreen.html">https://faculty.washington.edu/chudler/java/redgreen.html</ext-link>.</mixed-citation>
              </ref>
              <ref id="pone.0242169.ref031">
                <label>31</label>
                <mixed-citation publication-type="journal"><name><surname>Landis</surname><given-names>JR</given-names></name>, <name><surname>Koch</surname><given-names>GG</given-names></name>. <article-title>The measurement of observer agreement for categorical data</article-title>. <source>Biometrics</source>. <year>1977</year>;<volume>33</volume>(<issue>1</issue>):<fpage>159</fpage>–<lpage>74</lpage>. <?supplied-pmid 843571?><pub-id pub-id-type="pmid">843571</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0242169.ref032">
                <label>32</label>
                <mixed-citation publication-type="journal"><name><surname>van Amerongen</surname><given-names>G</given-names></name>, <name><surname>de Boer</surname><given-names>MW</given-names></name>, <name><surname>Groeneveld</surname><given-names>GJ</given-names></name>, <name><surname>Hay</surname><given-names>JL</given-names></name>. <article-title>A literature review on the pharmacological sensitivity of human evoked hyperalgesia pain models</article-title>. <source>Br J Clin Pharmacol</source>. <year>2016</year>:<fpage>903</fpage>–<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1111/bcp.13018</pub-id> .<?supplied-pmid 27203797?><pub-id pub-id-type="pmid">27203797</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0242169.ref033">
                <label>33</label>
                <mixed-citation publication-type="journal"><name><surname>Ilkjaer</surname><given-names>S</given-names></name>, <name><surname>Petersen</surname><given-names>KL</given-names></name>, <name><surname>Brennum</surname><given-names>J</given-names></name>, <name><surname>Wernberg</surname><given-names>M</given-names></name>, <name><surname>Dahl</surname><given-names>JB</given-names></name>. <article-title>Effect of systemic N-methyl-D-aspartate receptor antagonist (ketamine) on primary and secondary hyperalgesia in humans</article-title>. <source>Br J Anaesth</source>. <year>1996</year>;<volume>76</volume>(<issue>6</issue>):<fpage>829</fpage>–<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1093/bja/76.6.829</pub-id> .<?supplied-pmid 8679358?><pub-id pub-id-type="pmid">8679358</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0242169.ref034">
                <label>34</label>
                <mixed-citation publication-type="journal"><name><surname>Warncke</surname><given-names>T</given-names></name>, <name><surname>Stubhaug</surname><given-names>A</given-names></name>, <name><surname>Jorum</surname><given-names>E</given-names></name>. <article-title>Preinjury treatment with morphine or ketamine inhibits the development of experimentally induced secondary hyperalgesia in man</article-title>. <source>Pain</source>. <year>2000</year>;<volume>86</volume>(<issue>3</issue>):<fpage>293</fpage>–<lpage>303</lpage>. <pub-id pub-id-type="doi">10.1016/s0304-3959(00)00260-8</pub-id> .<?supplied-pmid 10812259?><pub-id pub-id-type="pmid">10812259</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0242169.ref035">
                <label>35</label>
                <mixed-citation publication-type="journal"><name><surname>Warncke</surname><given-names>T</given-names></name>, <name><surname>Stubhaug</surname><given-names>A</given-names></name>, <name><surname>Jorum</surname><given-names>E</given-names></name>. <article-title>Ketamine, an NMDA receptor antagonist, suppresses spatial and temporal properties of burn-induced secondary hyperalgesia in man: A double-blind, cross-over comparison with morphine and placebo</article-title>. <source>Pain</source>. <year>1997</year>;<volume>72</volume>(<issue>1–2</issue>):<fpage>99</fpage>–<lpage>106</lpage>. <pub-id pub-id-type="doi">10.1016/s0304-3959(97)00006-7</pub-id> .<?supplied-pmid 9272793?><pub-id pub-id-type="pmid">9272793</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0242169.ref036">
                <label>36</label>
                <mixed-citation publication-type="journal"><name><surname>Warncke</surname><given-names>T</given-names></name>, <name><surname>Jorum</surname><given-names>E</given-names></name>, <name><surname>Stubhaug</surname><given-names>A</given-names></name>. <article-title>Local treatment with the N-methyl-D-aspartate receptor antagonist ketamine, inhibit development of secondary hyperalgesia in man by a peripheral action</article-title>. <source>Neurosci Lett</source>. <year>1997</year>;<volume>227</volume>(<issue>1</issue>):<fpage>1</fpage>–<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1016/s0304-3940(97)00263-2</pub-id> .<?supplied-pmid 9178844?><pub-id pub-id-type="pmid">9178844</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0242169.ref037">
                <label>37</label>
                <mixed-citation publication-type="journal"><name><surname>Moiniche</surname><given-names>S</given-names></name>, <name><surname>Dahl</surname><given-names>JB</given-names></name>, <name><surname>Kehlet</surname><given-names>H</given-names></name>. <article-title>Peripheral antinociceptive effects of morphine after burn injury</article-title>. <source>Acta Anaesthesiol Scand</source>. <year>1993</year>;<volume>37</volume>(<issue>7</issue>):<fpage>710</fpage>–<lpage>2</lpage>. <pub-id pub-id-type="doi">10.1111/j.1399-6576.1993.tb03795.x</pub-id> .<?supplied-pmid 8249563?><pub-id pub-id-type="pmid">8249563</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0242169.ref038">
                <label>38</label>
                <mixed-citation publication-type="journal"><name><surname>Stubhaug</surname><given-names>A</given-names></name>, <name><surname>Romundstad</surname><given-names>L</given-names></name>, <name><surname>Kaasa</surname><given-names>T</given-names></name>, <name><surname>Breivik</surname><given-names>H</given-names></name>. <article-title>Methylprednisolone and ketorolac rapidly reduce hyperalgesia around a skin burn injury and increase pressure pain thresholds</article-title>. <source>Acta Anaesthesiol Scand</source>. <year>2007</year>;<volume>51</volume>(<issue>9</issue>):<fpage>1138</fpage>–<lpage>46</lpage>. <pub-id pub-id-type="doi">10.1111/j.1399-6576.2007.01415.x</pub-id> .<?supplied-pmid 17714578?><pub-id pub-id-type="pmid">17714578</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0242169.ref039">
                <label>39</label>
                <mixed-citation publication-type="journal"><name><surname>Petersen</surname><given-names>KL</given-names></name>, <name><surname>Brennum</surname><given-names>J</given-names></name>, <name><surname>Dahl</surname><given-names>JB</given-names></name>. <article-title>Experimental evaluation of the analgesic effect of ibuprofen on primary and secondary hyperalgesia</article-title>. <source>Pain</source>. <year>1997</year>;<volume>70</volume>(<issue>2–3</issue>):<fpage>167</fpage>–<lpage>74</lpage>. <pub-id pub-id-type="doi">10.1016/s0304-3959(96)03316-7</pub-id>
<?supplied-pmid 9150290?><pub-id pub-id-type="pmid">9150290</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0242169.ref040">
                <label>40</label>
                <mixed-citation publication-type="journal"><name><surname>Lundell</surname><given-names>JC</given-names></name>, <name><surname>Silverman</surname><given-names>DG</given-names></name>, <name><surname>Brull</surname><given-names>SJ</given-names></name>, <name><surname>O'Connor</surname><given-names>TZ</given-names></name>, <name><surname>Kitahata</surname><given-names>LM</given-names></name>, <name><surname>Collins</surname><given-names>JG</given-names></name>, <etal>et al</etal><article-title>Reduction of postburn hyperalgesia after local injection of ketorolac in healthy volunteers</article-title>. <source>Anesthesiology</source>. <year>1996</year>;<volume>84</volume>(<issue>3</issue>):<fpage>502</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1097/00000542-199603000-00003</pub-id>
<?supplied-pmid 8659776?><pub-id pub-id-type="pmid">8659776</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0242169.ref041">
                <label>41</label>
                <mixed-citation publication-type="journal"><name><surname>Pedersen</surname><given-names>JL</given-names></name>, <name><surname>Kehlet</surname><given-names>H</given-names></name>. <article-title>Hyperalgesia in a human model of acute inflammatory pain: A methodological study</article-title>. <source>Pain</source>. <year>1998</year>;<volume>74</volume>(<issue>2–3</issue>):<fpage>139</fpage>–<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1016/s0304-3959(97)00160-7</pub-id> .<?supplied-pmid 9520228?><pub-id pub-id-type="pmid">9520228</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0242169.ref042">
                <label>42</label>
                <mixed-citation publication-type="journal"><name><surname>Cavallone</surname><given-names>LF</given-names></name>, <name><surname>Frey</surname><given-names>K</given-names></name>, <name><surname>Montana</surname><given-names>MC</given-names></name>, <name><surname>Joyal</surname><given-names>J</given-names></name>, <name><surname>Regina</surname><given-names>KJ</given-names></name>, <name><surname>Petersen</surname><given-names>KL</given-names></name>, <etal>et al</etal><article-title>Reproducibility of the heat/capsaicin skin sensitization model in healthy volunteers</article-title>. <source>J Pain Res</source>. <year>2013</year>;<volume>6</volume>:<fpage>771</fpage>–<lpage>84</lpage>. <pub-id pub-id-type="doi">10.2147/JPR.S53437</pub-id>
<?supplied-pmid 24232380?><pub-id pub-id-type="pmid">24232380</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0242169.ref043">
                <label>43</label>
                <mixed-citation publication-type="journal"><name><surname>Werner</surname><given-names>MU</given-names></name>, <name><surname>Lassen</surname><given-names>B</given-names></name>, <name><surname>Pedersen</surname><given-names>JL</given-names></name>, <name><surname>Kehlet</surname><given-names>H</given-names></name>. <article-title>Local cooling does not prevent hyperalgesia following burn injury in humans</article-title>. <source>Pain</source>. <year>2002</year>;<volume>98</volume>(<issue>3</issue>):<fpage>297</fpage>–<lpage>303</lpage>. <pub-id pub-id-type="doi">10.1016/s0304-3959(02)00030-1</pub-id> .<?supplied-pmid 12127031?><pub-id pub-id-type="pmid">12127031</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0242169.ref044">
                <label>44</label>
                <mixed-citation publication-type="journal"><name><surname>Werner</surname><given-names>MU</given-names></name>, <name><surname>Duun</surname><given-names>P</given-names></name>, <name><surname>Kehlet</surname><given-names>H</given-names></name>. <article-title>Prediction of Postoperative Pain by Preoperative Nociceptive Responses to Heat Stimulation</article-title>. <source>Anesthesiology</source>. <year>2004</year>;<volume>100</volume>(<issue>1</issue>):<fpage>115</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1097/00000542-200401000-00020</pub-id> .<?supplied-pmid 14695732?><pub-id pub-id-type="pmid">14695732</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0242169.ref045">
                <label>45</label>
                <mixed-citation publication-type="journal"><name><surname>Pedersen</surname><given-names>JL</given-names></name>, <name><surname>Moiniche</surname><given-names>S</given-names></name>, <name><surname>Kehlet</surname><given-names>H</given-names></name>. <article-title>Topical glucocorticoid has no antinociceptive or anti-inflammatory effect in thermal injury</article-title>. <source>Br J Anaesth</source>. <year>1994</year>;<volume>72</volume>(<issue>4</issue>):<fpage>379</fpage>–<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1093/bja/72.4.379</pub-id> .<?supplied-pmid 8155434?><pub-id pub-id-type="pmid">8155434</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0242169.ref046">
                <label>46</label>
                <mixed-citation publication-type="journal"><name><surname>Werner</surname><given-names>MU</given-names></name>, <name><surname>Petersen</surname><given-names>KL</given-names></name>, <name><surname>Rowbotham</surname><given-names>MC</given-names></name>, <name><surname>Dahl</surname><given-names>JB</given-names></name>. <article-title>Healthy volunteers can be phenotyped using cutaneous sensitization pain models</article-title>. <source>PLoS One</source>. <year>2013</year>;<volume>8</volume>(<issue>5</issue>):<fpage>e62733</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0062733</pub-id><?supplied-pmid 23671631?><pub-id pub-id-type="pmid">23671631</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0242169.ref047">
                <label>47</label>
                <mixed-citation publication-type="journal"><name><surname>Eisenach</surname><given-names>JC</given-names></name>. <article-title>Preventing chronic pain after surgery: who, how, and when?</article-title><source>Reg Anesth Pain Med</source>. <year>2006</year>;<volume>31</volume>(<issue>1</issue>):<fpage>1</fpage>–<lpage>3</lpage>. <pub-id pub-id-type="doi">10.1016/j.rapm.2005.11.008</pub-id> .<?supplied-pmid 16418016?><pub-id pub-id-type="pmid">16418016</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0242169.ref048">
                <label>48</label>
                <mixed-citation publication-type="journal"><name><surname>Lavand'homme</surname><given-names>P</given-names></name>, <name><surname>De Kock</surname><given-names>M</given-names></name>. <article-title>The use of intraoperative epidural or spinal analgesia modulates postoperative hyperalgesia and reduces residual pain after major abdominal surgery</article-title>. <source>Acta Anaesthesiol Belg</source>. <year>2006</year>;<volume>57</volume>(<issue>4</issue>):<fpage>373</fpage>–<lpage>9</lpage>. .<?supplied-pmid 17236639?><pub-id pub-id-type="pmid">17236639</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0242169.ref049">
                <label>49</label>
                <mixed-citation publication-type="journal"><name><surname>Martinez</surname><given-names>V</given-names></name>, <name><surname>Ben Ammar</surname><given-names>S</given-names></name>, <name><surname>Judet</surname><given-names>T</given-names></name>, <name><surname>Bouhassira</surname><given-names>D</given-names></name>, <name><surname>Chauvin</surname><given-names>M</given-names></name>, <name><surname>Fletcher</surname><given-names>D</given-names></name>. <article-title>Risk factors predictive of chronic postsurgical neuropathic pain: the value of the iliac crest bone harvest model</article-title>. <source>Pain</source>. <year>2012</year>;<volume>153</volume>(<issue>7</issue>):<fpage>1478</fpage>–<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1016/j.pain.2012.04.004</pub-id> .<?supplied-pmid 22560289?><pub-id pub-id-type="pmid">22560289</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0242169.ref050">
                <label>50</label>
                <mixed-citation publication-type="journal"><name><surname>Stubhaug</surname><given-names>A</given-names></name>, <name><surname>Breivik</surname><given-names>H</given-names></name>, <name><surname>Eide</surname><given-names>PK</given-names></name>, <name><surname>Kreunen</surname><given-names>M</given-names></name>, <name><surname>Foss</surname><given-names>A</given-names></name>. <article-title>Mapping of punctuate hyperalgesia around a surgical incision demonstrates that ketamine is a powerful suppressor of central sensitization to pain following surgery</article-title>. <source>Acta Anaesthesiol Scand</source>. <year>1997</year>;<volume>41</volume>(<issue>9</issue>):<fpage>1124</fpage>–<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1111/j.1399-6576.1997.tb04854.x</pub-id> .<?supplied-pmid 9366932?><pub-id pub-id-type="pmid">9366932</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0242169.ref051">
                <label>51</label>
                <mixed-citation publication-type="journal"><name><surname>Martinez</surname><given-names>V</given-names></name>, <name><surname>Cymerman</surname><given-names>A</given-names></name>, <name><surname>Ben Ammar</surname><given-names>S</given-names></name>, <name><surname>Fiaud</surname><given-names>JF</given-names></name>, <name><surname>Rapon</surname><given-names>C</given-names></name>, <name><surname>Poindessous</surname><given-names>F</given-names></name>, <etal>et al</etal><article-title>The analgesic efficiency of combined pregabalin and ketamine for total hip arthroplasty: a randomised, double-blind, controlled study</article-title>. <source>Anaesthesia</source>. <year>2014</year>;<volume>69</volume>(<issue>1</issue>):<fpage>46</fpage>–<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1111/anae.12495</pub-id> .<?supplied-pmid 24320856?><pub-id pub-id-type="pmid">24320856</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0242169.ref052">
                <label>52</label>
                <mixed-citation publication-type="journal"><name><surname>Mercieri</surname><given-names>M</given-names></name>, <name><surname>Palmisani</surname><given-names>S</given-names></name>, <name><surname>De Blasi</surname><given-names>RA</given-names></name>, <name><surname>D'Andrilli</surname><given-names>A</given-names></name>, <name><surname>Naccarato</surname><given-names>A</given-names></name>, <name><surname>Silvestri</surname><given-names>B</given-names></name>, <etal>et al</etal><article-title>Low-dose buprenorphine infusion to prevent postoperative hyperalgesia in patients undergoing major lung surgery and remifentanil infusion: a double-blind, randomized, active-controlled trial</article-title>. <source>Br J Anaesth</source>. <year>2017</year>;<volume>119</volume>(<issue>4</issue>):<fpage>792</fpage>–<lpage>802</lpage>. <pub-id pub-id-type="doi">10.1093/bja/aex174</pub-id> .<?supplied-pmid 29121294?><pub-id pub-id-type="pmid">29121294</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0242169.ref053">
                <label>53</label>
                <mixed-citation publication-type="book"><name><surname>Watson</surname><given-names>MS</given-names></name>, <name><surname>Lucas</surname><given-names>CF</given-names></name>, <name><surname>Hoy</surname><given-names>AM</given-names></name>, <name><surname>Wells</surname><given-names>J</given-names></name>. <chapter-title>Principles of drug use in palliative care</chapter-title> In: <name><surname>Watson</surname><given-names>MS</given-names></name>, <name><surname>Lucas</surname><given-names>CF</given-names></name>, <name><surname>Hoy</surname><given-names>AM</given-names></name>, <name><surname>Wells</surname><given-names>J</given-names></name>, editors. <source>Oxford Handbook of Palliative Care</source>. <edition designator="2">2nd</edition> ed. <publisher-loc>Oxford, UK</publisher-loc>: '<publisher-name>Oxford University Press</publisher-name>'; <year>2009</year> p. <fpage>35</fpage>–<lpage>80</lpage>.</mixed-citation>
              </ref>
              <ref id="pone.0242169.ref054">
                <label>54</label>
                <mixed-citation publication-type="journal"><name><surname>Frost</surname><given-names>JJ</given-names></name>, <name><surname>Douglass</surname><given-names>KH</given-names></name>, <name><surname>Mayberg</surname><given-names>HS</given-names></name>, <name><surname>Dannals</surname><given-names>RF</given-names></name>, <name><surname>Links</surname><given-names>JM</given-names></name>, <name><surname>Wilson</surname><given-names>AA</given-names></name>, <etal>et al</etal><article-title>Multicompartmental analysis of [11C]-carfentanil binding to opiate receptors in humans measured by positron emission tomography</article-title>. <source>J Cereb Blood Flow Metab</source>. <year>1989</year>;<volume>9</volume>(<issue>3</issue>):<fpage>398</fpage>–<lpage>409</lpage>. <pub-id pub-id-type="doi">10.1038/jcbfm.1989.59</pub-id> .<?supplied-pmid 2541148?><pub-id pub-id-type="pmid">2541148</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0242169.ref055">
                <label>55</label>
                <mixed-citation publication-type="journal"><name><surname>Cohen</surname><given-names>MR</given-names></name>, <name><surname>Cohen</surname><given-names>RM</given-names></name>, <name><surname>Pickar</surname><given-names>D</given-names></name>, <name><surname>Weingartner</surname><given-names>H</given-names></name>, <name><surname>Murphy</surname><given-names>DL</given-names></name>. <article-title>High-dose naloxone infusions in normals. Dose-dependent behavioral, hormonal, and physiological responses</article-title>. <source>Arch Gen Psychiatry</source>. <year>1983</year>;<volume>40</volume>(<issue>6</issue>):<fpage>613</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1001/archpsyc.1983.04390010023003</pub-id> .<?supplied-pmid 6303264?><pub-id pub-id-type="pmid">6303264</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0242169.ref056">
                <label>56</label>
                <mixed-citation publication-type="journal"><name><surname>Edwards</surname><given-names>RR</given-names></name>, <name><surname>Ness</surname><given-names>TJ</given-names></name>, <name><surname>Fillingim</surname><given-names>RB</given-names></name>. <article-title>Endogenous opioids, blood pressure, and diffuse noxious inhibitory controls: a preliminary study</article-title>. <source>Percept Mot Skills</source>. <year>2004</year>;<volume>99</volume>(<issue>2</issue>):<fpage>679</fpage>–<lpage>87</lpage>. <pub-id pub-id-type="doi">10.2466/pms.99.2.679-687</pub-id> .<?supplied-pmid 15560360?><pub-id pub-id-type="pmid">15560360</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0242169.ref057">
                <label>57</label>
                <mixed-citation publication-type="journal"><name><surname>Cohen</surname><given-names>MR</given-names></name>, <name><surname>Cohen</surname><given-names>RM</given-names></name>, <name><surname>Pickar</surname><given-names>D</given-names></name>, <name><surname>Weingartner</surname><given-names>H</given-names></name>, <name><surname>Murphy</surname><given-names>DL</given-names></name>, <name><surname>Bunney</surname><given-names>WE</given-names><suffix>Jr</suffix></name>. <article-title>Behavioural effects after high dose naloxone administration to normal volunteers</article-title>. <source>Lancet</source>. <year>1981</year>;<volume>2</volume>(<issue>8255</issue>):<fpage>1110</fpage><pub-id pub-id-type="doi">10.1016/s0140-6736(81)91308-8</pub-id> .<?supplied-pmid 6118553?><pub-id pub-id-type="pmid">6118553</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0242169.ref058">
                <label>58</label>
                <mixed-citation publication-type="journal"><name><surname>Cohen</surname><given-names>MR</given-names></name>, <name><surname>Cohen</surname><given-names>RM</given-names></name>, <name><surname>Pickar</surname><given-names>D</given-names></name>, <name><surname>Murphy</surname><given-names>DL</given-names></name>. <article-title>Naloxone reduces food intake in humans</article-title>. <source>Psychosom Med</source>. <year>1985</year>;<volume>47</volume>(<issue>2</issue>):<fpage>132</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1097/00006842-198503000-00004</pub-id> .<?supplied-pmid 4048359?><pub-id pub-id-type="pmid">4048359</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0242169.ref059">
                <label>59</label>
                <mixed-citation publication-type="journal"><name><surname>Cohen</surname><given-names>MR</given-names></name>, <name><surname>Cohen</surname><given-names>RM</given-names></name>, <name><surname>Pickar</surname><given-names>D</given-names></name>, <name><surname>Kreger</surname><given-names>D</given-names></name>, <name><surname>McLellan</surname><given-names>C</given-names></name>, <name><surname>Murphy</surname><given-names>DL</given-names></name>. <article-title>Hormonal effects of high dose naloxone in humans</article-title>. <source>Neuropeptides</source>. <year>1985</year>;<volume>6</volume>(<issue>4</issue>):<fpage>373</fpage>–<lpage>80</lpage>. <pub-id pub-id-type="doi">10.1016/0143-4179(85)90010-1</pub-id> .<?supplied-pmid 3930990?><pub-id pub-id-type="pmid">3930990</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0242169.ref060">
                <label>60</label>
                <mixed-citation publication-type="journal"><name><surname>Cohen</surname><given-names>MR</given-names></name>, <name><surname>Cohen</surname><given-names>RM</given-names></name>, <name><surname>Pickar</surname><given-names>D</given-names></name>, <name><surname>Murphy</surname><given-names>DL</given-names></name>, <name><surname>Bunney</surname><given-names>WE</given-names><suffix>Jr</suffix></name>. <article-title>Physiological effects of high dose naloxone administration to normal adults</article-title>. <source>Life Sci</source>. <year>1982</year>;<volume>30</volume>(<issue>23</issue>):<fpage>2025</fpage>–<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1016/0024-3205(82)90443-x</pub-id> .<?supplied-pmid 6287138?><pub-id pub-id-type="pmid">6287138</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0242169.ref061">
                <label>61</label>
                <mixed-citation publication-type="journal"><name><surname>Cohen</surname><given-names>MR</given-names></name>, <name><surname>Cohen</surname><given-names>RM</given-names></name>, <name><surname>Pickar</surname><given-names>D</given-names></name>, <name><surname>Sunderland</surname><given-names>T</given-names></name>, <name><surname>Mueller</surname><given-names>EA 3rd</given-names></name>, <name><surname>Murphy</surname><given-names>DL</given-names></name>. <article-title>High dose naloxone in depression</article-title>. <source>Biol Psychiatry</source>. <year>1984</year>;<volume>19</volume>(<issue>6</issue>):<fpage>825</fpage>–<lpage>32</lpage>. .<?supplied-pmid 6743720?><pub-id pub-id-type="pmid">6743720</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0242169.ref062">
                <label>62</label>
                <mixed-citation publication-type="journal"><name><surname>Cohen</surname><given-names>MR</given-names></name>, <name><surname>Pickar</surname><given-names>D</given-names></name>, <name><surname>Cohen</surname><given-names>RM</given-names></name>. <article-title>High-dose naloxone administration in chronic schizophrenia</article-title>. <source>Biol Psychiatry</source>. <year>1985</year>;<volume>20</volume>(<issue>5</issue>):<fpage>573</fpage>–<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1016/0006-3223(85)90030-7</pub-id> .<?supplied-pmid 3886025?><pub-id pub-id-type="pmid">3886025</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0242169.ref063">
                <label>63</label>
                <mixed-citation publication-type="journal"><name><surname>Adams</surname><given-names>HP</given-names><suffix>Jr.</suffix></name>, <name><surname>Olinger</surname><given-names>CP</given-names></name>, <name><surname>Barsan</surname><given-names>WG</given-names></name>, <name><surname>Butler</surname><given-names>MJ</given-names></name>, <name><surname>Graff-Radford</surname><given-names>NR</given-names></name>, <name><surname>Brott</surname><given-names>TG</given-names></name>, <etal>et al</etal><article-title>A dose-escalation study of large doses of naloxone for treatment of patients with acute cerebral ischemia</article-title>. <source>Stroke</source>. <year>1986</year>;<volume>17</volume>(<issue>3</issue>):<fpage>404</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1161/01.str.17.3.404</pub-id> .<?supplied-pmid 3715936?><pub-id pub-id-type="pmid">3715936</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0242169.ref064">
                <label>64</label>
                <mixed-citation publication-type="journal"><name><surname>Barsan</surname><given-names>WG</given-names></name>, <name><surname>Olinger</surname><given-names>CP</given-names></name>, <name><surname>Adams</surname><given-names>HP</given-names><suffix>Jr</suffix></name>., <name><surname>Brott</surname><given-names>TG</given-names></name>, <name><surname>Eberle</surname><given-names>R</given-names></name>, <name><surname>Biller</surname><given-names>J</given-names></name>, <etal>et al</etal><article-title>Use of high dose naloxone in acute stroke: possible side-effects</article-title>. <source>Crit Care Med</source>. <year>1989</year>;<volume>17</volume>(<issue>8</issue>):<fpage>762</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1097/00003246-198908000-00009</pub-id> .<?supplied-pmid 2752771?><pub-id pub-id-type="pmid">2752771</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0242169.ref065">
                <label>65</label>
                <mixed-citation publication-type="journal"><name><surname>Olinger</surname><given-names>CP</given-names></name>, <name><surname>Adams</surname><given-names>HP</given-names><suffix>Jr</suffix></name>., <name><surname>Brott</surname><given-names>TG</given-names></name>, <name><surname>Biller</surname><given-names>J</given-names></name>, <name><surname>Barsan</surname><given-names>WG</given-names></name>, <name><surname>Toffol</surname><given-names>GJ</given-names></name>, <etal>et al</etal><article-title>High-dose intravenous naloxone for the treatment of acute ischemic stroke</article-title>. <source>Stroke</source>. <year>1990</year>;<volume>21</volume>(<issue>5</issue>):<fpage>721</fpage>–<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1161/01.str.21.5.721</pub-id> .<?supplied-pmid 2339451?><pub-id pub-id-type="pmid">2339451</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0242169.ref066">
                <label>66</label>
                <mixed-citation publication-type="journal"><name><surname>Federico</surname><given-names>F</given-names></name>, <name><surname>Lucivero</surname><given-names>V</given-names></name>, <name><surname>Lamberti</surname><given-names>P</given-names></name>, <name><surname>Fiore</surname><given-names>A</given-names></name>, <name><surname>Conte</surname><given-names>C</given-names></name>. <article-title>A double blind randomized pilot trial of naloxone in the treatment of acute ischemic stroke</article-title>. <source>Ital J Neurol Sci</source>. <year>1991</year>;<volume>12</volume>(<issue>6</issue>):<fpage>557</fpage>–<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1007/BF02336951</pub-id> .<?supplied-pmid 1783533?><pub-id pub-id-type="pmid">1783533</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0242169.ref067">
                <label>67</label>
                <mixed-citation publication-type="journal"><name><surname>Papathanasiou</surname><given-names>T</given-names></name>, <name><surname>Springborg</surname><given-names>AD</given-names></name>, <name><surname>Kongstad</surname><given-names>KT</given-names></name>, <name><surname>Staerk</surname><given-names>D</given-names></name>, <name><surname>Moller</surname><given-names>K</given-names></name>, <name><surname>Taylor</surname><given-names>BK</given-names></name>, <etal>et al</etal><article-title>High-dose naloxone, an experimental tool uncovering latent sensitisation: pharmacokinetics in humans</article-title>. <source>Br J Anaesth</source>. <year>2019</year>;<volume>123</volume>(<issue>2</issue>):<fpage>e204</fpage>–<lpage>e14</lpage>. <pub-id pub-id-type="doi">10.1016/j.bja.2018.12.007</pub-id> .<?supplied-pmid 30915992?><pub-id pub-id-type="pmid">30915992</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0242169.ref068">
                <label>68</label>
                <mixed-citation publication-type="journal"><name><surname>Kim</surname><given-names>S</given-names></name>, <name><surname>Wagner</surname><given-names>HN</given-names><suffix>Jr</suffix></name>., <name><surname>Villemagne</surname><given-names>VL</given-names></name>, <name><surname>Kao</surname><given-names>PF</given-names></name>, <name><surname>Dannals</surname><given-names>RF</given-names></name>, <name><surname>Ravert</surname><given-names>HT</given-names></name>, <etal>et al</etal><article-title>Longer occupancy of opioid receptors by nalmefene compared to naloxone as measured in vivo by a dual-detector system</article-title>. <source>J Nucl Med</source>. <year>1997</year>;<volume>38</volume>(<issue>11</issue>):<fpage>1726</fpage>–<lpage>31</lpage>. <?supplied-pmid 9374341?><pub-id pub-id-type="pmid">9374341</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0242169.ref069">
                <label>69</label>
                <mixed-citation publication-type="journal"><name><surname>Yassen</surname><given-names>A</given-names></name>, <name><surname>Olofsen</surname><given-names>E</given-names></name>, <name><surname>van Dorp</surname><given-names>E</given-names></name>, <name><surname>Sarton</surname><given-names>E</given-names></name>, <name><surname>Teppema</surname><given-names>L</given-names></name>, <name><surname>Danhof</surname><given-names>M</given-names></name>, <etal>et al</etal><article-title>Mechanism-based pharmacokinetic-pharmacodynamic modelling of the reversal of buprenorphine-induced respiratory depression by naloxone: a study in healthy volunteers</article-title>. <source>Clin Pharmacokinet</source>. <year>2007</year>;<volume>46</volume>(<issue>11</issue>):<fpage>965</fpage>–<lpage>80</lpage>. <pub-id pub-id-type="doi">10.2165/00003088-200746110-00004</pub-id> .<?supplied-pmid 17922561?><pub-id pub-id-type="pmid">17922561</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0242169.ref070">
                <label>70</label>
                <mixed-citation publication-type="journal"><name><surname>De Felice</surname><given-names>M</given-names></name>, <name><surname>Sanoja</surname><given-names>R</given-names></name>, <name><surname>Wang</surname><given-names>R</given-names></name>, <name><surname>Vera-Portocarrero</surname><given-names>L</given-names></name>, <name><surname>Oyarzo</surname><given-names>J</given-names></name>, <name><surname>King</surname><given-names>T</given-names></name>, <etal>et al</etal><article-title>Engagement of descending inhibition from the rostral ventromedial medulla protects against chronic neuropathic pain</article-title>. <source>Pain</source>. <year>2011</year>;<volume>152</volume>(<issue>12</issue>):<fpage>2701</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.pain.2011.06.008</pub-id>
<?supplied-pmid 21745713?><pub-id pub-id-type="pmid">21745713</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0242169.ref071">
                <label>71</label>
                <mixed-citation publication-type="journal"><name><surname>Custodio-Patsey</surname><given-names>L</given-names></name>, <name><surname>Donahue</surname><given-names>RR</given-names></name>, <name><surname>Fu</surname><given-names>W</given-names></name>, <name><surname>Lambert</surname><given-names>J</given-names></name>, <name><surname>Smith</surname><given-names>BN</given-names></name>, <name><surname>Taylor</surname><given-names>BK</given-names></name>. <article-title>Sex differences in kappa opioid receptor inhibition of latent postoperative pain sensitization in dorsal horn</article-title>. <source>Neuropharmacology</source>. <year>2020</year>;<volume>163</volume>:<fpage>107726</fpage><pub-id pub-id-type="doi">10.1016/j.neuropharm.2019.107726</pub-id><?supplied-pmid 31351975?><pub-id pub-id-type="pmid">31351975</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0242169.ref072">
                <label>72</label>
                <mixed-citation publication-type="journal"><name><surname>Solway</surname><given-names>B</given-names></name>, <name><surname>Bose</surname><given-names>SC</given-names></name>, <name><surname>Corder</surname><given-names>G</given-names></name>, <name><surname>Donahue</surname><given-names>RR</given-names></name>, <name><surname>Taylor</surname><given-names>BK</given-names></name>. <article-title>Tonic inhibition of chronic pain by neuropeptide Y</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2011</year>;<volume>108</volume>(<issue>17</issue>):<fpage>7224</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1017719108</pub-id>
<?supplied-pmid 21482764?><pub-id pub-id-type="pmid">21482764</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0242169.ref073">
                <label>73</label>
                <mixed-citation publication-type="journal"><name><surname>Fu</surname><given-names>W</given-names></name>, <name><surname>Nelson</surname><given-names>TS</given-names></name>, <name><surname>Santos</surname><given-names>DF</given-names></name>, <name><surname>Doolen</surname><given-names>S</given-names></name>, <name><surname>Gutierrez</surname><given-names>JJP</given-names></name>, <name><surname>Ye</surname><given-names>N</given-names></name>, <etal>et al</etal><article-title>An NPY Y1 receptor antagonist unmasks latent sensitization and reveals the contribution of protein kinase A and Epac to chronic inflammatory pain</article-title>. <source>Pain</source>. <year>2019</year>;<volume>160</volume>(<issue>8</issue>):<fpage>1754</fpage>–<lpage>65</lpage>. <pub-id pub-id-type="doi">10.1097/j.pain.0000000000001557</pub-id>
<?supplied-pmid 31335645?><pub-id pub-id-type="pmid">31335645</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0242169.ref074">
                <label>74</label>
                <mixed-citation publication-type="journal"><name><surname>Santos</surname><given-names>DD</given-names></name>, <name><surname>Custodio-Patsey</surname><given-names>L</given-names></name>, <name><surname>Donahue</surname><given-names>R</given-names></name>, <name><surname>Oliveira-Fusaro</surname><given-names>M</given-names></name>, <name><surname>Taylor</surname><given-names>B</given-names></name>. <article-title>Does a long-lasting, analgesic synergy develop between spinal mu opioid receptors and neuropeptide Y1Rs after surgical incision? [abstract]</article-title>. <source>J Pain</source>. <year>2017</year>;<volume>18</volume>(<issue>4</issue>):<fpage>S26</fpage><pub-id pub-id-type="doi">10.1016/j.jpain.2017.02.107</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0242169.ref075">
                <label>75</label>
                <mixed-citation publication-type="journal"><name><surname>Nair</surname><given-names>AB</given-names></name>, <name><surname>Jacob</surname><given-names>S</given-names></name>. <article-title>A simple practice guide for dose conversion between animals and human</article-title>. <source>J Basic Clin Pharm</source>. <year>2016</year>;<volume>7</volume>(<issue>2</issue>):<fpage>27</fpage>–<lpage>31</lpage>. <pub-id pub-id-type="doi">10.4103/0976-0105.177703</pub-id>
<?supplied-pmid 27057123?><pub-id pub-id-type="pmid">27057123</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0242169.ref076">
                <label>76</label>
                <mixed-citation publication-type="journal"><name><surname>Bryant</surname><given-names>CD</given-names></name>, <name><surname>Zhang</surname><given-names>NN</given-names></name>, <name><surname>Sokoloff</surname><given-names>G</given-names></name>, <name><surname>Fanselow</surname><given-names>MS</given-names></name>, <name><surname>Ennes</surname><given-names>HS</given-names></name>, <name><surname>Palmer</surname><given-names>AA</given-names></name>, <etal>et al</etal><article-title>Behavioral differences among C57BL/6 substrains: implications for transgenic and knockout studies</article-title>. <source>J Neurogenet</source>. <year>2008</year>;<volume>22</volume>(<issue>4</issue>):<fpage>315</fpage>–<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1080/01677060802357388</pub-id>
<?supplied-pmid 19085272?><pub-id pub-id-type="pmid">19085272</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0242169.ref077">
                <label>77</label>
                <mixed-citation publication-type="journal"><name><surname>Mogil</surname><given-names>JS</given-names></name>, <name><surname>Wilson</surname><given-names>SG</given-names></name>, <name><surname>Bon</surname><given-names>K</given-names></name>, <name><surname>Lee</surname><given-names>SE</given-names></name>, <name><surname>Chung</surname><given-names>K</given-names></name>, <name><surname>Raber</surname><given-names>P</given-names></name>, <etal>et al</etal><article-title>Heritability of nociception I: responses of 11 inbred mouse strains on 12 measures of nociception</article-title>. <source>Pain</source>. <year>1999</year>;<volume>80</volume>(<issue>1–2</issue>):<fpage>67</fpage>–<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1016/s0304-3959(98)00197-3</pub-id> .<?supplied-pmid 10204719?><pub-id pub-id-type="pmid">10204719</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0242169.ref078">
                <label>78</label>
                <mixed-citation publication-type="journal"><name><surname>Mogil</surname><given-names>JS</given-names></name>, <name><surname>Wilson</surname><given-names>SG</given-names></name>, <name><surname>Bon</surname><given-names>K</given-names></name>, <name><surname>Lee</surname><given-names>SE</given-names></name>, <name><surname>Chung</surname><given-names>K</given-names></name>, <name><surname>Raber</surname><given-names>P</given-names></name>, <etal>et al</etal><article-title>Heritability of nociception II. 'Types' of nociception revealed by genetic correlation analysis</article-title>. <source>Pain</source>. <year>1999</year>;<volume>80</volume>(<issue>1–2</issue>):<fpage>83</fpage>–<lpage>93</lpage>. <pub-id pub-id-type="doi">10.1016/s0304-3959(98)00196-1</pub-id> .<?supplied-pmid 10204720?><pub-id pub-id-type="pmid">10204720</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0242169.ref079">
                <label>79</label>
                <mixed-citation publication-type="journal"><name><surname>Matre</surname><given-names>D</given-names></name>, <name><surname>Casey</surname><given-names>KL</given-names></name>, <name><surname>Knardahl</surname><given-names>S</given-names></name>. <article-title>Placebo-induced changes in spinal cord pain processing</article-title>. <source>J Neurosci</source>. <year>2006</year>;<volume>26</volume>(<issue>2</issue>):<fpage>559</fpage>–<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.4218-05.2006</pub-id> WOS:000234556200025. <?supplied-pmid 16407554?><pub-id pub-id-type="pmid">16407554</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
          <sub-article id="pone.0242169.r001" article-type="aggregated-review-documents">
            <front-stub>
              <article-id pub-id-type="doi">10.1371/journal.pone.0242169.r001</article-id>
              <title-group>
                <article-title>Decision Letter 0</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Farag</surname>
                    <given-names>Ehab</given-names>
                  </name>
                  <role>Academic Editor</role>
                </contrib>
              </contrib-group>
              <permissions>
                <copyright-statement>© 2020 Ehab Farag</copyright-statement>
                <copyright-year>2020</copyright-year>
                <copyright-holder>Ehab Farag</copyright-holder>
                <license xlink:href="http://creativecommons.org/licenses/by/4.0/">
                  <license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
                </license>
              </permissions>
              <related-article id="rel-obj001" ext-link-type="doi" xlink:href="10.1371/journal.pone.0242169" related-article-type="reviewed-article"/>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>Submission Version</meta-name>
                  <meta-value>0</meta-value>
                </custom-meta>
              </custom-meta-group>
            </front-stub>
            <body>
              <p>
                <named-content content-type="letter-date">11 Sep 2020</named-content>
              </p>
              <p>PONE-D-20-21906</p>
              <p>High-dose naloxone: Effects by late administration on pain and hyperalgesia following a human heat injury model.</p>
              <p>A randomized, double-blind, placebo-controlled, crossover trial with an enriched enrollment design.</p>
              <p>PLOS ONE</p>
              <p>Dear Dr. Anders Deichmann Springborg</p>
              <p>Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.</p>
              <p>==============================</p>
              <p>I would appreciate to pay a careful attention in your revision to the reviewer's comments.</p>
              <p>
                <list list-type="bullet">
                  <list-item>
                    <p> </p>
                  </list-item>
                </list>
              </p>
              <p>Please ensure that your decision is justified on PLOS ONE’s <ext-link ext-link-type="uri" xlink:href="https://journals.plos.org/plosone/s/criteria-for-publication">publication criteria</ext-link> and not, for example, on novelty or perceived impact.</p>
              <p>==============================</p>
              <p>Please submit your revised manuscript by Oct 26 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at <email>plosone@plos.org</email>. When you're ready to submit your revision, log on to <ext-link ext-link-type="uri" xlink:href="https://www.editorialmanager.com/pone/">https://www.editorialmanager.com/pone/</ext-link> and select the 'Submissions Needing Revision' folder to locate your manuscript file.</p>
              <p>Please include the following items when submitting your revised manuscript:</p>
              <p>
                <list list-type="bullet">
                  <list-item>
                    <p>A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.</p>
                  </list-item>
                  <list-item>
                    <p>A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.</p>
                  </list-item>
                  <list-item>
                    <p>An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.</p>
                  </list-item>
                </list>
              </p>
              <p>If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.</p>
              <p>If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: <ext-link ext-link-type="uri" xlink:href="http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols">http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols</ext-link></p>
              <p>We look forward to receiving your revised manuscript.</p>
              <p>Kind regards,</p>
              <p>Ehab Farag, MD FRCA FASA</p>
              <p>Academic Editor</p>
              <p>PLOS ONE</p>
              <p>Journal Requirements:</p>
              <p>When submitting your revision, we need you to address these additional requirements.</p>
              <p>1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at</p>
              <p><ext-link ext-link-type="uri" xlink:href="https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf">https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf</ext-link> and</p>
              <p>
                <ext-link ext-link-type="uri" xlink:href="https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf">https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf</ext-link>
              </p>
              <p>2. In your Methods section, please provide additional information about the participant recruitment method and the demographic details of your participants. Please ensure you have provided sufficient details to replicate the analyses such as:   a) a table of relevant demographic details, and b) descriptions of where participants were recruited and where the research took place.</p>
              <p>[Note: HTML markup is below. Please do not edit.]</p>
              <p>Reviewers' comments:</p>
              <p>Reviewer's Responses to Questions</p>
              <p>
                <bold>Comments to the Author</bold>
              </p>
              <p>1. Is the manuscript technically sound, and do the data support the conclusions?</p>
              <p>The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. </p>
              <p>Reviewer #1: Partly</p>
              <p>**********</p>
              <p>2. Has the statistical analysis been performed appropriately and rigorously? </p>
              <p>Reviewer #1: No</p>
              <p>**********</p>
              <p>3. Have the authors made all data underlying the findings in their manuscript fully available?</p>
              <p>The <ext-link ext-link-type="uri" xlink:href="http://www.plosone.org/static/policies.action#sharing">PLOS Data policy</ext-link> requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.</p>
              <p>Reviewer #1: Yes</p>
              <p>**********</p>
              <p>4. Is the manuscript presented in an intelligible fashion and written in standard English?</p>
              <p>PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.</p>
              <p>Reviewer #1: Yes</p>
              <p>**********</p>
              <p>5. Review Comments to the Author</p>
              <p>Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)</p>
              <p>Reviewer #1: The study entitled ‘High-dose naloxone: Effects by late administration on pain and hyperalgesia following a human heat injury model. A randomized, double-blind, placebo-controlled, crossover trial with an enriched enrollment design’ with the aim to examine the association between injury-induced secondary hyperalgesia and naloxone-induced unmasking of latent sensitization.</p>
              <p>This is quite an interesting study but the manuscript requires further improvement.</p>
              <p>Comments</p>
              <p>Methods</p>
              <p>Participants &amp; Enrichment</p>
              <p>Page 7 Line 113-114, it was stated ‘Two subjects from Q4 were excluded before Session 1 for reasons unrelated to the trial,’ but in Page 8 Line 129-130, ‘Subjects in Q4 (n = 20) and Q1 (n = 20) continued to experimental Sessions 1 to 4.</p>
              <p>Randomization procedure</p>
              <p>Page 8 Line 142- 143 &amp; Figure 1, randomization procedure and cross-over design not clear. More information to be provided.</p>
              <p>Drugs administration</p>
              <p>Page 9-10 Line 165-173 &amp; Page 10-11 175-182, the section to be placed at their respective section write-up.</p>
              <p>Page 11 Line 191-196, the section to be placed with Session 2 and 4.</p>
              <p>Pain during the cutaneous heat injury</p>
              <p>Page 12 Line 223, full name for AUC/s to be provided.</p>
              <p>Sample size calculation</p>
              <p>Page 13 Line 249, the word ‘high-variance data’ not clear and requires revision.</p>
              <p>Statistical analysis</p>
              <p>Paired samples t-test and Unpaired samples t test to be written as paired t test and unpaired t test respectively throughout the manuscript.</p>
              <p>Page 14 Line 263, the exact type of Wilcoxon test to be stated.</p>
              <p>Page 14 Page Line 266-267, ‘time (Session 2, 4 [post hoc cf. Results - Protocol violations])’ requires rewording.</p>
              <p>Page 14 Line 268-269. the sentence ‘Factors (P &gt; 0.05), beginning with interactions, were excluded until all included factors attained significance.’ requires fine tuning.</p>
              <p>Adjustment on p value/CI if any to be stated. Effect size could be used where applicable.</p>
              <p>The order/sequence presentation of the write-up in the methodology requires improvements.</p>
              <p>Results</p>
              <p>The word Median and 95%CI or Mean and 95% CI to be used throughout the manuscript. For 95%CI, lower ‘to’ upper limit, the word ‘to’ to be replaced with symbol dash’-’</p>
              <p>Validity of the enrichment procedure</p>
              <p>Page 16 Line 310-311, word median to be stated.</p>
              <p>Pairwise comparison</p>
              <p>Page 17 Line 324, 326-328, the sentence not clear weather comparing sessions or between groups. The use of Wilcoxon signed rank for what comparison to be clearly stated.</p>
              <p>Page 18 Line 334-337 &amp; 345-347, word median (95% CI) and word ‘estimate’ and ‘95% CI’ to be stated.</p>
              <p>Page 18 Line 337, statistical test to be denoted.</p>
              <p>Mixed-effects model</p>
              <p>Page 18 Line 346, results to be placed in table.</p>
              <p>Mechanical pain thresholds</p>
              <p>Page 19, Line 364, what method use to correcting baseline to be clearly stated.</p>
              <p>Page 19 365-366, statistical test to be stated.</p>
              <p>Page 20 Line 368-373, mean (95% CI) to be stated where necessary.</p>
              <p>No difference to be stated as no significance difference or the difference was not statistically significant.</p>
              <p>References to follow journal format.</p>
              <p>**********</p>
              <p>6. PLOS authors have the option to publish the peer review history of their article (<ext-link ext-link-type="uri" xlink:href="https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history">what does this mean?</ext-link>). If published, this will include your full peer review and any attached files.</p>
              <p>If you choose “no”, your identity will remain anonymous but your review may still be made public.</p>
              <p><bold>Do you want your identity to be public for this peer review?</bold> For information about this choice, including consent withdrawal, please see our <ext-link ext-link-type="uri" xlink:href="https://www.plos.org/privacy-policy">Privacy Policy</ext-link>.</p>
              <p>Reviewer #1: No</p>
              <p>[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]</p>
              <p>While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <ext-link ext-link-type="uri" xlink:href="https://pacev2.apexcovantage.com/">https://pacev2.apexcovantage.com/</ext-link>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at <email>figures@plos.org</email>. Please note that Supporting Information files do not need this step.</p>
            </body>
          </sub-article>
          <sub-article id="pone.0242169.r002" article-type="author-comment">
            <front-stub>
              <article-id pub-id-type="doi">10.1371/journal.pone.0242169.r002</article-id>
              <title-group>
                <article-title>Author response to Decision Letter 0</article-title>
              </title-group>
              <related-article id="rel-obj002" ext-link-type="doi" xlink:href="10.1371/journal.pone.0242169" related-article-type="editor-report"/>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>Submission Version</meta-name>
                  <meta-value>1</meta-value>
                </custom-meta>
              </custom-meta-group>
            </front-stub>
            <body>
              <p>
                <named-content content-type="author-response-date">24 Oct 2020</named-content>
              </p>
              <p>A. Comments to the Editor concerning ‘Journal Requirements’</p>
              <p>1. The authors have ensured that the manuscript meets PLOS ONE style requirements, including those for file naming. </p>
              <p>2. In the Methods section, the authors have provided relevant, additional information about the participant recruitment and the laboratory environment. A table of relevant demographic details has already been provided (Table 3).</p>
              <p>B. Comments to the Reviewer</p>
              <p>The authors acknowledge with gratitude the effort in preparing the evaluation of the manuscript. Thank you. The authors consider the suggestions and queries for having improved the manuscript significantly.</p>
              <p>REVIEWER #1: The study entitled ‘High-dose naloxone: Effects by late administration on pain and hyperalgesia following a human heat injury model. A randomized, double-blind, placebo-controlled, crossover trial with an enriched enrollment design’ with the aim to examine the association between injury-induced secondary hyperalgesia and naloxone-induced unmasking of latent sensitization.</p>
              <p>This is quite an interesting study, but the manuscript requires further improvement.</p>
              <p>We thank the Reviewer for the compliment, and we will do our best to comply with the comments and queries.</p>
              <p>COMMENTS:</p>
              <p>Methods: Participants &amp; Enrichment (Q1)</p>
              <p>Q1: Page 7 Line 113-114, it was stated ‘Two subjects from Q4 were excluded before Session 1 for reasons unrelated to the trial,’ but in Page 8 Line 129-130, ‘Subjects in Q4 (n = 20) and Q1 (n = 20) continued to experimental Sessions 1 to 4.</p>
              <p>R1: We agree that these seeming contradictions may confuse the reader. The sentence: ‘Subjects in Q4 (n = 20) and Q1 (n = 20) continued to experimental Sessions 1 to 4’ refers to the fact that the 20 subjects from the upper quartile (Q4) and the 20 subjects from the lower quartile (Q1) were planned to continue forward to the experimental sessions (1-4). However, after the randomization (prior to participation in Session 1), two subjects were discontinued; thus, no other subjects took their place. The sentence: ‘Two subjects from Q4 were excluded before Session 1 for reasons unrelated to the trial’, is actually from a figure caption, which adds to the confusion. The information in the sections has been updated.</p>
              <p>Randomization procedure (Q2)</p>
              <p>Q2: Page 8 Line 142- 143 &amp; Figure 1, randomization procedure and crossover design not clear. More information to be provided.</p>
              <p>R2: We thank the Reviewer for pointing this out. We have tried to make the information about the randomization procedure clearer.</p>
              <p>Regarding Figure 1, this has been updated with information on how many subjects received the allocation. Further, we have made an attempt to make the phases of the enrichment, randomization, and allocation process clearer.</p>
              <p>Drugs administration (Q3-Q4)</p>
              <p>Q3: Page 9-10, Line 165-173 &amp; Page 10-11 175-182, the section to be placed at their respective section write-up.</p>
              <p>R3: The two sections are figure captions, which by PLOS ONE requirements should be placed after the first paragraph where they are cited. We, therefore, believe that the sections are correctly placed.</p>
              <p>Q4: Page 11, Line 191-196, the section to be placed with Session 2 and 4.</p>
              <p>R4: The section referred to by the Reviewer contains information about the cutaneous heat injury, which is induced in the subjects in Sessions 0, 1, and 3. We, therefore, do not believe that the section should be placed together with Sessions 2 and 4 (drug administration sessions). However, we agree that it is more logical to place the section before information about the drug infusion, since this makes more sense from a chronological aspect. Therefore, the ‘Cutaneous heat injury’ section has been moved to before the ‘Drug administration’ section (Page 9, Line 163-168).</p>
              <p>Pain during the cutaneous heat injury (Q5-Q6)</p>
              <p>Q5: Page 12, Line 223, full name for AUC/s to be provided.</p>
              <p>R5: We thank the Reviewer for pointing this out. The full name for AUC/s has been provided as ‘area under the curve per second’ (Page 12, Line 233).</p>
              <p>Sample size calculation (Q6)</p>
              <p>Q6: Page 13, Line 249, the word ‘high-variance data’ not clear and requires revision.</p>
              <p>R6: We agree that the wording might be misunderstood. Changes have been made to the sentence. </p>
              <p>Statistical analysis (Q8-Q12)</p>
              <p>Q7: Paired samples t-test and Unpaired samples t test to be written as paired t test and unpaired t test respectively throughout the manuscript.</p>
              <p>R7: We thank the Reviewer for pointing this out. Paired samples t-test and unpaired samples t-test have been corrected to paired t test and unpaired t test, respectively, throughout the manuscript.</p>
              <p>Q8: Page 14, Line 263, the exact type of Wilcoxon test to be stated.</p>
              <p>R8: The Wilcoxon test has been specified as the Wilcoxon signed-rank test (Page 14, Line 273).</p>
              <p>Q9: Page 14 Page Line 266-267, ‘time (Session 2, 4 [post hoc cf. Results - Protocol violations])’ requires rewording.</p>
              <p>R9: We agree with the Reviewer that the sentence requires rewording and therefore changes have been made to the sentence.</p>
              <p>Q10: Page 14, Line 268-269. the sentence ‘Factors (P &gt; 0.05), beginning with interactions, were excluded until all included factors attained significance.’ requires fine tuning.</p>
              <p>R10: We have adjusted the sentence regarding the exclusion of factors in the mixed-effects model. Further, amendments have been made in the Statistical analysis section regarding the mixed-effects model.</p>
              <p>Q11: Adjustment on p value/CI if any to be stated. Effect size could be used where applicable.</p>
              <p>R11: Regarding the adjustment on p-value/CI, we assume that the Reviewer means if we used any multiple testing correction. We have not used any such corrections. However, a general adjustment on p-value has been made in the sense that a conservative significance level of 0.01 was used. </p>
              <p>Regarding effect size, our co-author biostatistician (MAP) recommends that we, for the mixed-effects model and other statistical analyses, instead use estimates (mean differences) with CI (as we have done) since these are more clinically relevant. </p>
              <p>Q12: The order/sequence presentation of the write-up in the methodology requires improvements.</p>
              <p>R12: We agree that the order of sections in the Methods could be improved. As mentioned in R4, we have moved the ‘Cutaneous heat injury’ section to before the ‘Drug administration’ section. </p>
              <p>Results (Q13)</p>
              <p>Q13: The word Median and 95%CI or Mean and 95% CI to be used throughout the manuscript. For 95%CI, lower ‘to’ upper limit, the word ‘to’ to be replaced with symbol dash ’-’</p>
              <p>R13: We agree that adding mean and median increases the ease of reading. The words median (95% CI) and mean (95% CI) have been added throughout the manuscript. Additionally, ‘to’ has been replaced with the symbol dash ‘–‘ for all confidence intervals. A longer dash was used since some confidence intervals contain negative values and therefore included a short dash ‘-‘ before the number.</p>
              <p>Validity of the enrichment procedure (Q14)</p>
              <p>Q14: Page 16, Line 310-311, word median to be stated.</p>
              <p>R14: The word ‘median [95% CI]’ has been added to the sentence (Page 17, Line 322-323).</p>
              <p>Pairwise comparison (Q15-Q17)</p>
              <p>Q15: Page 17, Line 324, 326-328, the sentence not clear weather comparing sessions or between groups. The use of Wilcoxon signed rank for what comparison to be clearly stated.</p>
              <p>R15: We acknowledge that the sentence may be confusing. Thus, the section has been updated.</p>
              <p>Q16: Page 18 Line 334-337 &amp; 345-347, word median (95% CI) and word ‘estimate’ and ‘95% CI’ to be stated.</p>
              <p>R16: The Reviewer is correct, and ‘median [95% CI]’ and ‘estimate [95% CI]’ have been added for the first section (Figure 6 caption [Page 18, Line 349-351]). However, for the second section, the numbers (except p-values) have been deleted (Page 18, Line 361-363; cf. R18) </p>
              <p>Q17: Page 18, Line 337, statistical test to be denoted.</p>
              <p>R17: The statistical test, Mann-Whitney U test, has been denoted. Additionally, the statistical test has been denoted as Wilcoxon signed-rank test (Figure 6 caption [Page 18, Line 450]).</p>
              <p>Mixed-effects model (Q18)</p>
              <p>Q18: Page 18 Line 346, results to be placed in table.</p>
              <p>R18: By recommendation from our co-author biostatistician (MAP), the results referred to by the Reviewer have been included in a new Table 6 (Page 20, Line 376-379). Further, changes have been made to the 'Mixed-effects model' paragraph (Page 18, Line 360-362)</p>
              <p>Mechanical pain thresholds (Q19-Q23)</p>
              <p>Q19: Page 19, Line 364, what method use to correcting baseline to be clearly stated.</p>
              <p>R19: The method for baseline correction was clarified (Page 20, Line 384-385)</p>
              <p>Q20: Page 19 365-366, statistical test to be stated.</p>
              <p>R20: We apologize for the mistake and have added the statistical test, Wilcoxon signed-rank test (Page 21, Line 387-388).</p>
              <p>Q21: Page 20 Line 368-373, mean (95% CI) to be stated where necessary.</p>
              <p>R21: The word ‘mean (95% CI)’ has been stated wherever necessary (Page 21, Line 390-396). </p>
              <p>Q22: No difference to be stated as no significance difference or the difference was not statistically significant.</p>
              <p>R22: The appropriate wording has been changed wherever necessary. </p>
              <p>Q23: References to follow journal format.</p>
              <p>R23: The corresponding author and the senior author both have perused the references and are not able to retrieve any bibliographical errors or typos. </p>
              <p>For a more detailed response to the Reviewer and Editor's comments, please see the 'Response to Reviewers' letter.</p>
            </body>
          </sub-article>
          <sub-article id="pone.0242169.r003" article-type="editor-report">
            <front-stub>
              <article-id pub-id-type="doi">10.1371/journal.pone.0242169.r003</article-id>
              <title-group>
                <article-title>Decision Letter 1</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Farag</surname>
                    <given-names>Ehab</given-names>
                  </name>
                  <role>Academic Editor</role>
                </contrib>
              </contrib-group>
              <permissions>
                <copyright-statement>© 2020 Ehab Farag</copyright-statement>
                <copyright-year>2020</copyright-year>
                <copyright-holder>Ehab Farag</copyright-holder>
                <license xlink:href="http://creativecommons.org/licenses/by/4.0/">
                  <license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
                </license>
              </permissions>
              <related-article id="rel-obj003" ext-link-type="doi" xlink:href="10.1371/journal.pone.0242169" related-article-type="reviewed-article"/>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>Submission Version</meta-name>
                  <meta-value>1</meta-value>
                </custom-meta>
              </custom-meta-group>
            </front-stub>
            <body>
              <p>
                <named-content content-type="letter-date">28 Oct 2020</named-content>
              </p>
              <p>High-dose naloxone: Effects by late administration on pain and hyperalgesia following a human heat injury model.</p>
              <p>A randomized, double-blind, placebo-controlled, crossover trial with an enriched enrollment design.</p>
              <p>PONE-D-20-21906R1</p>
              <p>Dear Dr. Anders Deichmann Springborg</p>
              <p>We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.</p>
              <p>Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.</p>
              <p>An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at <ext-link ext-link-type="uri" xlink:href="http://www.editorialmanager.com/pone/">http://www.editorialmanager.com/pone/</ext-link>, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at <email>authorbilling@plos.org</email>.</p>
              <p>If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <email>onepress@plos.org</email>.</p>
              <p>Kind regards,</p>
              <p>Ehab Farag, MD FRCA FASA</p>
              <p>Academic Editor</p>
              <p>PLOS ONE</p>
              <p>Additional Editor Comments (optional):</p>
              <p>Reviewers' comments:</p>
            </body>
          </sub-article>
          <sub-article id="pone.0242169.r004" article-type="editor-report">
            <front-stub>
              <article-id pub-id-type="doi">10.1371/journal.pone.0242169.r004</article-id>
              <title-group>
                <article-title>Acceptance letter</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Farag</surname>
                    <given-names>Ehab</given-names>
                  </name>
                  <role>Academic Editor</role>
                </contrib>
              </contrib-group>
              <permissions>
                <copyright-statement>© 2020 Ehab Farag</copyright-statement>
                <copyright-year>2020</copyright-year>
                <copyright-holder>Ehab Farag</copyright-holder>
                <license xlink:href="http://creativecommons.org/licenses/by/4.0/">
                  <license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
                </license>
              </permissions>
              <related-article id="rel-obj004" ext-link-type="doi" xlink:href="10.1371/journal.pone.0242169" related-article-type="reviewed-article"/>
            </front-stub>
            <body>
              <p>
                <named-content content-type="letter-date">5 Nov 2020</named-content>
              </p>
              <p>PONE-D-20-21906R1 </p>
              <p>High-dose naloxone: Effects by late administration on pain and hyperalgesia following a human heat injury model.
A randomized, double-blind, placebo-controlled, crossover trial with an enriched enrollment design </p>
              <p>Dear Dr. Springborg:</p>
              <p>I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. </p>
              <p>If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <email>onepress@plos.org</email>.</p>
              <p>If we can help with anything else, please email us at <email>plosone@plos.org</email>. </p>
              <p>Thank you for submitting your work to PLOS ONE and supporting open access. </p>
              <p>Kind regards, </p>
              <p>PLOS ONE Editorial Office Staff</p>
              <p>on behalf of</p>
              <p>Dr. Ehab Farag </p>
              <p>Academic Editor</p>
              <p>PLOS ONE</p>
            </body>
          </sub-article>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
